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Zusammenfassung 
 
Im Rahmen dieser Arbeit sollte erstmals die Rolle des Autoantigens p62, das in HCC 
Tumoren nachgewiesen werden konnte, mit Hilfe eines Mausmodells untersucht 
werden. Hierzu wurden Mäuse generiert, die das humane p62 Protein unter Kontrolle 
des liver enriched activator proteins (LAP) leberspezifisch exprimieren. 
 
Aufgrund der postulierten insulin-like growth factor 2 (IGF2) mRNA-bindenden 
Eigenschaft von p62 wurde vermutet, dass p62 die Expression des metabolischen 
Wachstumsfaktors IGF2 regulieren könnte.  
 
In der Tat zeigten Untersuchungen einen starken Anstieg der IGF2 und H19 
Expression in p62 transgenen Tieren. Dabei übt p62 weder einen Einfluss auf die 
mRNA Stabilität aus, noch verursacht es eine Änderung der Allel-spezifischen 
Expression von IGF2 und H19.  
 
Mit Auftreten der höchsten IGF2 Expression in p62 transgenen Tieren konnte 
gleichzeitig der Phänotyp einer Fettleber zu einem frühen Alterszeitpunkt gezeigt 
werden. 
 
Untersuchungen von Zielstrukturen, die IGF2-vermittelt reguliert werden, konnten 
eine Aktivierung von AKT sowie eine Inaktiverung von PTEN zeigen. Nachdem diese 
Ergebnisse einen anti-apoptotischen Phänotyp vermuten ließen, wurde die 
Apoptoserate anhand der Caspase-3-Aktivität bestimmt. In Hepatozyten aus p62 
transgenen Tieren konnte in der Tat ein Schutz vor induzierter Apoptose 
nachgewiesen werden. 
 
Der Zusammenhang zwischen erhöhter p62, IGF2 und H19 Expression konnte 
abschließend mit Hilfe eines RNA-Interferenz Ansatzes im menschlichen System 
untermauert werden. 
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Abstract 
 
Although p62 was originally identified to be highly expressed in HCC tissue, its 
potential functional implications in liver disease have as yet been completely 
unknown. Therefore, aim of this work was to elucidate functional implications of 
hepatic overexpression of the tumor-associated autoantigen p62. This is why liver-
specific p62 transgenic mice were generated, which express hup62 under control of 
the liver enriched activator protein (LAP). 
 
Due to the IGF2 mRNA-binding properties of p62, a potential regulation of IGF2, a 
metabolically active growth factor, was hypothesized.  
 
In fact, a highly increased expression of IGF2 and the closely associated H19 RNA, 
with which it shares an imprinting control region, could be demonstrated. 
 
Investigations on IGF2 and H19 mRNA stability in isolated hepatocytes employing 
the transcription inhibitor actinomycin D (ActD) revealed no alterations in mRNA 
turnover upon p62 expression. Since IGF2 and H19 are imprinted genes, allele-
specific expression of both genes was investigated. However, no changes in allele-
specific expression could be determined upon expression of p62. 
 
Histological examinations showed the phenotype of a fatty liver in p62 transgenic 
mice at a very early age when also IGF2 expression was highest.  
 
Regarding potential IGF2 downstream targets, PTEN was downregulated in p62 
transgenic animals, whereas an increase in the phosphorylation of AKT was 
demonstrated.  
 
Since a respective signalling status might exert anti-apoptotic actions, apoptotic cell 
death was determined, measured as caspase-3-like activity. In fact, a decrease upon 
ActD/TNF-α induced apoptosis manifested in hepatocytes from p62 transgenic mice. 
 
In order to investigate the causal correlation between increased IGF2 and H19 and 
p62 overexpression also in a human system, siRNA-mediated knockdown of p62 was 
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performed in human hepatoma cell lines confirming p62 as a regulator of both IGF2 
and H19.  
 
In summary, these results for the first time characterize functional implications of p62 
overexpression and suggest the induction of an anti-apoptotic, fatty liver phenotype. 
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1.  Introduction  
 
1.1   Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC) are primary 
maligant liver cancers. HCC is the sixth most common cancer worldwide in terms of 
numbers of cases (5.7%) and the third most common cause of death from cancer. 
500,000 to 800,000 incidences per year are observed with areas of high incidence 
(50-150 cases per 100,000 inhabitants) in parts of South East Asia and Africa (Figure 
1). In Germany, each year 6,000 newly diagnosed cases are registered. The overall 
sex ratio (male: female) is around 2.4 (Parkin, Bray et al. 2005). 
 
In most cases, HCC is developing from chronic liver cirrhosis caused by Hepatitis B 
and C virus infection, chronic alcohol consumption or hemochromatosis. Aflatoxins 
promote tumorigenesis in the case of an exisiting Hepatitis B, which might be a 
reason for the high incidence in the tropical areas of the world where food is 
frequently contaminated with the fungus Aspergillus (Yeh, Yu et al. 1989). 
 
 
 
 Figure 1: Age standardized incidence for liver cancer. Data show  
   incidences per 100,000 by sex (source:http://rafscience.com). 
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Recently, states of insulin resistance like obesity, diabetes mellitus, non-alcoholic 
fatty liver disease (NAFLD), and non-alcoholic steatohepatititis (NASH) have 
increasingly shown to represent metabolic risk factors contributing to HCC.  
 
These diseases might explain the rise in incidence, which doubled in men and 
women in the industrialized countries including the U. K. and Germany over the past 
20 years (Cancer Research UK) (Figure 2). 
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Figure 2:  Rates of incidence of primary liver cancer in Saarland, Germany  
between 1976 and 2006 (source: www.krebsregister.saarland.de) 
 
 
Overall survival (3-5%) shows a poor prognosis due to the lack of efficient systemic 
treatment options, leading to an average life span of about six month after diagnosis. 
As the molecular factors and interactions involved in hepatocarcinogenesis are 
poorly understood, it is necessary to gain an understanding of the pathogenesis to 
improve therapeutic treatment. Malignant transformation of hepatocytes may occur 
through an increase in liver cell turnover due to chronic liver injury and regeneration 
in a context of inflammation, immune response, and oxidative DNA damage, leading 
to genetic alterations. This may result in the activation of oncogenes, the inactivation 
of tumor suppressor genes or the overexpression of growth factors (Yang and Rogler 
1991). 
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1.2   NASH 
 
NAFLD encompasses a wide spectrum of diseases ranging from triglyceride 
accumulation in hepatocytes (hepatic steatosis) without and with inflammation 
(steatohepatitis), fibrosis, and cirrhosis (Neuschwander-Tetri and Caldwell 2003). 
NAFLD is more and more recognized as a major cause of liver-related morbidity and 
mortality due to its potential to promote the development of metabolic disorders, 
resulting in liver cirrhosis and HCC (Teli, James et al. 1995). NAFLD resembles the 
pathological picture of an alcohol induced liver disease but it is found in patients who 
do not abuse alcohol (Neuschwander-Tetri and Caldwell 2003). Meanwhile, this 
disease affects approximately 30 million Americans (Clark, Brancati et al. 2002) and 
prognosis prevalence is bad due to an increase in the epidemics diabetes and 
obesity.  
 
Day et al. proposed a “two-hit” model to explain the progression of NAFLD (Day and 
James 1998). The “first hit” constitutes the deposition of triglycerides in the cytoplasm 
of the hepatocyte whereas the “second hit” includes additional cellular events, e. g. 
inflammation, cell death and fibrosis, which progress the disease.  
 
1.3   The tumor-associated autoantigen p62 
 
p62 belongs to the family of insulin-like growth factor 2 (IGF2)-mRNA binding 
proteins (IMPs) containing two types of RNA-binding motifs, the consensus sequence 
RNA binding domain (CS-RBD) and four human heterogenous nuclear (hn) RNP K 
homology (KH) domains. These mRNA binding proteins contribute to tumorigenesis 
by regulating mRNA stability and localisation. Nielsen et al. showed in 1999 that 
IMPs bind to the 5´-sequence of the IGF2 leader 3 mRNA, thereby causing a 
translational repression of IGF2 expression (Nielsen, Christiansen et al. 1999). A 
potential regulation of IGF2 mRNA by p62 is of special interest since IGF2 has been 
shown to be overexpressed in HCC (Su, Schröder et al. 1998) and has been shown 
to promote tumors in transgenic mice (Christofori, Naik et al. 1994). p62 was 
originally isolated in 1999 (Zhang, Chan et al. 1999) as a 62 kDA autoantigen located 
in the cytoplasm of HCC tumor cells. It was demonstrated that p62 is 
developmentally regulated, i.e. it is expressed in malignant cancer cells as well as in 
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fetal tissue but it could not be detected in normal, non-neoplastic hepatocytes 
(Zhang, Zhu et al. 2001).  
 
1.4   DNA methylation 
 
DNA methylation is a type of chemical modification that can be inherited and 
subsequently removed without changing the original DNA sequence. Methylation and 
demethylation events of DNA are central to the epigenetic regulations in 
development (Russo, Tommasi et al. 1996). Beyond, DNA methylation is implicated 
in the regulation of transcription, in maintaining genome stability (i. e. by establishing 
the allele-specific expression status) and in the inactivation of the X-Chromosome (Li, 
Beard et al. 1993; Bestor 2000). The mechanisms controlling these events are of 
fundamental importance in developmental cell biology but also seem to be implicated 
in carcinogenesis and tumour progression (Patra, Patra et al. 2002). Only DNA 
methylation typically occurs in a CpG dinucleotide context. CpG stands for cytosine 
and guanine separated by a phosphate (—C—phosphate—G—), which links the two 
nucleosides together in DNA. 2-3 % of the mammalian genome contains methylated 
cytosines, whereby in mammals, most prominent is the methylation of the DNA on 
cytosine at the 5´-position in CpG dinucleotides, catalysed by DNA 
methyltransferases (DNMTs). Two enzyme classes are known, from which DNMT1 is 
responsible for methylation of the newly synthesized strand, thereby being essential 
for the maintainance of the DNA methylation pattern (Bestor 2000). DNA methylase 
MBD2 performs the reverse reaction (Bhattacharya, Ramchandani et al. 1999). 
 
Although DNMT2 shares high sequence homology with members of the DNA 
methyltransferase family, it was shown to have no DNA methyltransferase activity 
(Yoder and Bestor 1998). Surprisingly, DNMT2 represents an active RNA 
methyltransferase (Goll, Kirpekar et al. 2006).  
 
1.5   Genomic imprinting  
 
For the majority of genes both copies, one inherited from the father, one from the 
mother, are functional. However, in a small subset of genes, one copy is switched off 
in a parent-of-origin specific manner. These genes are called imprinted because one 
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copy is epigenetically marked leading to a monoallelic expression of the gene. 
Imprinting can vary between developmental stages, tissues, and species (Reik and 
Walter 2001). Paternally expressed imprinted genes tend to promote growth while it 
is suppressed by those genes that are maternally expressed.  
 
A genome-wide search for imprinted genes in the human genome with the use of 
computer-learning algorithms resulted in the identification of 156 novel candidate 
imprinted genes (Luedi, Dietrich et al. 2007). In 2008, the “catalogue of imprinted 
genes and parent-of-origin effects in humans and animals” contained 219 imprinted 
genes (http://igc.otago.ac.nz/Summary-table.pdf).  
 
The majority of imprinted genes show differences in DNA methylation between the 
parental alleles. Usually, a high density of cytosine-guanine dinucleotides (CpG) 
islands characterise imprinted genes. 
 
In 1983, Feinberg and Vogelstein reported differences in DNA methylation at CpG 
islands in tumors for the first time (Feinberg and Vogelstein 1983). A dysregulation of 
this functional haploid state by a single epigenomic change can cause tremendous 
health effects making imprinted genes a susceptible target for human pathologies. 
Imprinting associated diseases occur through early development (e. g. Beckwith-
Wiedemann, Prader-Willi or Angelman syndrome) or as cancer (e.g. breast, lung, 
liver, colorectal cancer) when altered later in life (Jirtle 1999). Moreover, imprinting 
disorders have an impact on metabolic diseases like diabetes mellitus or obesity. 
 
Allele-specific expression of genes was first detected in 1991 for the fetal growth-
factor IGF2, its receptor IGF2R and for H19 by restriction-fragment-length 
polymorphisms and RNAse protection assays (DeChiara, Robertson et al. 1991). 
 
Interestingly, imprinted genes are often arranged in clusters, i. e. imprinted genes are 
in vicinity of other imprinted genes. Activation of H19 expression on the maternal 
chromosome leads to the inactivation of the IGF2 gene, giving one example of two 
promotors competing for the same enhancer element, leading to a reciprocal gene 
expression. On the paternal allele, the IGF2 promotor drives IGF2 gene expression 
while at the same time inactivating H19 (Leighton, Saam et al. 1996). The imprinting 
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of IGF2 and H19 is controlled by a region located 4 kb upstream from the H19 
transcription unit, defined as the H19 differentially methylated region (DMR) or 
imprinting control region (ICR) (Thorvaldsen, Duran et al. 1998). 
 
1.6   The imprinted genes IGF2 and H19 
 
The genes for both IGF2 and H19 are mapped to a 90 kilobase (kb) region in a gene 
cluster on human chromosome 11p15.5 (Zemel, Bartolomei et al. 1992) and on the 
distal region of chromosome 7 in mice (Pachnis, Belayew et al. 1984). In the majority 
of human tissues, only the maternal allele of the H19 gene is expressed and only the 
paternal allele of the IGF2 gene is expressed. In liver, IGF2 is monoallelically 
expressed at birth, with a switch to biallelic expression during the first year of 
postnatal life (Ohlsson, Nystrom et al. 1993; Davies 1994; Ekström, Cui et al. 1995). 
In contrast, H19 is imprinted in normal human liver throughout life (Ekström, Cui et al. 
1995). Biallelic expression of IGF2 and H19 has been demonstrated in several 
paediatric (e. g. Wilms´ tumor) and adult malignancies (e.g. lung cancer) (Glassman, 
de Groot et al. 1996; Ross, Schmidt et al. 1999). 
 
1.6.1   H19 
 
The H19 gene encodes for a 2.3 kb non-coding RNA (Brunkow and Tilghman 1991). 
It was originally identified as a fetal liver-specific mRNA whose repression after birth 
paralleled that of the α-fetoprotein (AFP) gene (Pachnis, Belayew et al. 1984). 
 
Both genes are under the control of two trans-acting loci in the mouse, termed raf 
and Rif (Pachnis, Belayew et al. 1984). These loci determine the adult basal and 
inducible levels, i. e. they affect the transcription of H19 mRNA. The H19 gene is 
composed of five exons, along with four very small introns. Preceeding the 
translation initiation codon are four ATG codons, each of which is followed shortly 
thereafter by translation terminator codons (Pachnis, Brannan et al. 1988). This leads 
to H19 RNA transcription, splicing and poly-adenylation but probably not to 
translation. The localization of the H19 RNA to a cytoplasmic ribonucleoprotein 
(RNP) particle led to the conclusion that this RNA does not encode a protein 
(Brannan, Dees et al. 1990).  
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To identify the function of H19, several mouse models were established. The 
overexpression of H19 is lethal: mouse embryos die between day 14 and birth 
(Brunkow and Tilghman 1991). Loss of function of H19 does not lead to embryonic 
death in mice (Leighton, Saam et al. 1995). The overgrowth phenotype of H19 
deficient mice is most likely due to the biallelic expression of IGF2 (Ripoche, Kress et 
al. 1997). This is why H19 is supposed to act as a regulator of IGF2 (Leighton, Saam 
et al. 1995).  
 
The controversy whether H19 acts as a tumor suppressor or whether it promotes 
carcinogenesis has not yet been resolved, as numerous tumors display either over-
expression or lack of H19 expression (Matouk, DeGroot et al. 2007; Yoshimizu, 
Miroglio et al. 2008). 
 
Certain known carcinogens increase the level of H19. In this context 
diethylnitrosamine, a known carcinogen of the liver, has been regarded to induce 
H19 RNA expression in a mouse model (Graveel, Jatkoe et al. 2001). Also the c-Myc 
proto-oncogene plays an important role in the development of HCC (Coulouarn, 
Gomez-Quiroz et al. 2006) and is known to induce H19 expression (Barsyte-Lovejoy, 
Lau et al. 2006). H19 RNA is upregulated in HBV-associated HCC (Iizuka, Oka et al. 
2002). Furthermore, a biallelic expression of the H19 gene was found in human HCC 
patients (Kim and Lee 1997). 
 
Due to observations from Beckwith-Wiedemann syndrome, an overgrowth syndrome 
with an increased risk for embryonic tumors, it has been hypothesized that tumor 
predisposition is related to the 11p15.5 chromosomal region and the imprinting status 
at the H19-IGF2 locus, with a loss of imprinting (LOI) leading to a higher tumor risk 
(Rump, Zeegers et al. 2005).  
 
As a result of this observation, the H19-IGF2 locus can be looked upon as a tumor 
suppressor candidate. In vitro experiments support initial evidence that underline this 
hypothesis (Hao, Crenshaw et al. 1993). In vivo, the acceleration in the latency of 
appearance of SV40 induced tumors in mice was revealed in the absence of H19 
expression (Yoshimizu, Miroglio et al. 2008).  
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In addition, loss of the maternal and duplication of the paternal copy of the 
chromosomal region bearing the IGF2 and H19 genes occur at high frequency in 
HCC (Casola, Ungaro et al. 1995). These genetic events resemble the loss of 
heterozygosity (LOH) occurring at chromosome 11p15.5 loci in human cancers, 
result in the induction of IGF2, and lack of H19 expression. 
 
1.6.2  IGF2 
 
Insulin-like growth factor 2 (IGF-2) plays a key role in mammalian growth, influencing 
foetal cell division and differentiation and possibly metabolic regulation (Figure 3) 
(Nielsen 1992; O'Dell and Day 1998).  
 
 
Figure 3:  Interaction of IGF2 with its receptors and the multiple effects upon  
activation (source: (O'Dell and Day 1998)) 
 
 
The gene extends over approximately 12 kb of mouse chromosome 7 including six 
exons (Rotwein and Hall 1990). Exons 1-3 encode distinct 5'-untranslated regions 
and are transcribed by three different promoters, P1, P2, and P3, into three IGF2 
mRNAs sharing common coding and 3' untranslated sequences. Exons 4-6 code for 
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the 180 amino-acid IGF2 precursor and exon 6 contains a 3'-untranslated region, 
which ends at a single poly-adenylation site (Rotwein and Hall 1990).  
 
The mature 67 amino acid peptide shares sequence homology with both insulin and 
IGF1. The liver is the main endocrine source of IGFs, but autocrine/paracrine activity 
is found in most tissues (Moses, Nissley et al. 1980; Milner and Hill 1984). IGF2 
stimulates growth through the insulin-like growth factor I receptor (IGF-IR), a ligand-
activated tyrosine kinase (Baker, Liu et al. 1993). The IGF2 receptor appears to 
negatively regulate growth by targeting IGF2 to digestive lysosomes (Oka, Rozek et 
al. 1985).  
 
Heterozygous knockout of the IGF2 gene led to fetal growth restriction in mice 
(DeChiara, Efstratiadis et al. 1990). Transmission through the male germline resulted 
in heterozygous progeny, which were smaller than wild-type littermates (about 60% 
of normal body weight). In contrast, if knockout transmission occurred through the 
female germline, the offspring was phenotypically normal. 
 
Overexpression of IGF2 was detected in many tumours and for more than 20 years, 
it has been known that IGF2 contributes to tumorigenesis (Reeve, Eccles et al. 1985) 
through its anti-apoptotic and growth-stimulating effects (Pavelic, Bukovic et al. 
2002).  
 
Differential methylation of DNA in CpG islands is of fundamental importance in the 
maintainance of monoallelic gene expression (Li, Beard et al. 1993; Ward, Fisher et 
al. 1997). Transcription of the IGF2 gene is regulated by the H19 DMD region. On the 
paternal chromosome, the H19 DMD is methylated leading to the depression of the 
IGF2 promotor, while on the maternal chromosome the H19 DMD region is 
unmethylated. Loss of imprinting (LOI), resulting from the methylation of the maternal 
H19 DMD, leads to promoter activation on both alleles with the consequence of a 
biallelic IGF2 expression. This LOI might be a reason for IGF2 overexpression in 
tumors (Cui, Niemitz et al. 2001; Nakagawa, Chadwick et al. 2001). 
 
Moroever, three CpG-rich, differentially methylated regions (DMR 1, DMR 2 and 
DMR 3) are located in the IGF2 locus, playing a role in monoallelic expression during 
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embryogenesis (Feil, Walter et al. 1994; Moore, Constancia et al. 1997). Whereas 
DMR 1 has been shown to be a methylation sensitive silencer, methylation of DMR 2 
results in the upregulation of the IGF2 gene expression (Murrell, Heeson et al. 2001). 
In contrast to DMR 2, deletion of DMR 1 leads to silencing of IGF2 (Constancia, 
Dean et al. 2000). DMR 3 becomes temporarily demethylated before returning to the 
allele-specific pattern (Kuroiwa, Sakamoto et al. 2009). 
 
Christofori et al. (Christofori, Naik et al. 1995) observed that endogenous IGF2 gene 
expression was activated in precancerous lesions and islet cell carcinomas of the 
pancreas in transgenic mice, which express SV40 large T-antigen under regulation of 
the rat insulin promoter. To test the hypothesis that IGF2 has a functional role in the 
development of pancreatic tumors, SV40 T-antigen transgenic mice were crossed 
with IGF2-deficient mice (DeChiara, Efstratiadis et al. 1990; Christofori, Naik et al. 
1995). When tumors occured in the animals, a direct correlation was observed 
between the IGF2 gene and the volume of tumors formed in the pancreas. There was 
a fivefold higher apoptotic index in tumors which lacked IGF2, suggesting that IGF2 
plays a role in suppressing apoptosis. 
 
Evidence of IGF2 involvement in hepatocarcinogenesis was deduced from animal 
models as well as in human HCC. IGF2 reexpression in four independent mouse 
lines may contribute to hepatocarcinogenesis through an autocrine mechanism 
(Schirmacher, Held et al. 1992). Transforming-growth factor α (TGF-α) is reactivated 
during hepatocarcinogenesis. In TGFα- transgenic mice 100% of HCC expressed 
IGF2 with the paternal allele silent and the maternal allele activated (Harris, Rogler et 
al. 1998). A 40- to 100-fold increase in the level of IGF2 mRNA was detected in 22% 
of primary liver cancers (Cariani, Lasserre et al. 1988). This increase in liver IGF2 
transcripts is consistent with what was observed in a human hepatocellular 
carcinoma derived cell line (HepG2) (Koufos, Hansen et al. 1985). 
 
Growth promoting effects of IGF2 are mediated through binding to the IGF-IR. This 
binding induces activation through auto-phosphorylation of intracellular tyrosine 
residues. This follows the induction of downstream signal transduction pathways 
involved in differentiation, proliferation and apoptosis (O'Connor 1998): IGF-IR 
mediated signalling mainly induces the ERK 1/2 kinases and the PI3-kinase.  
 Introduction 19 
1.7   IGF2 downstream signalling pathways 
 
1.7.1  Phosphoinositide 3-kinase (PI3-kinase) 
 
The phosphatidylinositol 3-kinases (PI3-kinases) are a ubiquitously expressed 
enzyme family, playing a key role in the regulation of many cellular processes. They 
play a central role in cell survival and growth, vesicular trafficking, degranulation, 
cytoskeletal rearrangements and migration (Leevers, Vanhaesebroeck et al. 1999; 
Rameh and Cantley 1999). Hence, its potential role in cancer is of great interest. 
 
PI3-kinases are forming heterodimers, consisting of a regulatory and a catalytic 
subunit. The 3-phosphorylated inositol lipids fulfill roles as second messengers by 
interacting with the lipid binding domains of a variety of cellular proteins. They are 
activated by G-protein-coupled receptors or receptors with an intrinsic or associated 
protein tyrosine kinase activity and/or proteins that are tyrosine phosphorylated in 
response to extracellular stimuli (Kapeller and Cantley 1994). Another way in which 
PI3-kinases are activated is by a direct interaction with the small GTPase Ras 
(Rodriguez-Viciana, Warne et al. 1994; Rodriguez-Viciana, Marte et al. 1996). 
 
Phosphatidylinositol phosphates are composed of a membrane-associated 
phosphatidic acid group and a glycerol moiety that is linked to a cytosolic 
phosphorylated inositol head group (Figure 4).  
 
Figure 4:  Composition of phosphatidylinositol phosphates. 
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The hydroxyl residues of the inositol molecule can be phosphorylated in vivo at the 
3´- and 5´-position. Hence, these phosphorylated molecules are called 
phosphoinosites (PI). Phosphate transfer is mediated through PI-kinases. PI3-kinase 
transfers the terminal phosphate of adenosintriphosphate to the 3´-position of inositol 
(Divecha and Irvine 1995). Upon activation, these enzymes phosphorylate inositol 
lipids at the D-3 position of the inositol ring to generate the 3-phosphoinositides, 
phosphatidylinositol 3-phosphate [PtdIns(3)P], phosphatidyl-inositol 3,4-bisphosphate 
[PtdIns(3,4)P2] and phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3]. 
Phosphorylation at the D3 position is necessary for binding to the pleckstrin-
homology domain of AKT. 
 
The tumor suppressor protein PTEN is able to downregulate PI3-kinase lipid 
formation by its lipid phosphatase activity (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Schematic representation of the PI3-kinase pathway.  
Numerous cell surfacemolecules initiate PI3-kinase signalling. Upon 
phosphorylation PIP3 is formed, which in turn activates the AKT 
pathway. Thereby, certain downstream effectors are mediated. In the 
absence of PTEN, the AKT pathway is hyperactivated, leading to an 
increase in apoptosis resistance and enhanced cell proliferation 
(source: (Kishimoto, Hamada et al. 2003)) 
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Three classes of PI3-kinases have been defined on the basis of their primary 
structure, regulation, and in vitro lipid substrate specificity. Class I consists of four 
p110 catalytic isoforms which associate with the p85 family of regulatory subunits 
(Stephens, Eguinoa et al. 1997). Class II enzymes are large proteins, which all 
contain a characteristic C-terminal region with homology to C2 domains.  Class III 
enzymes only contain a catalytic and a phosphoinositide kinase domain 
(Vanhaesebroeck, Leevers et al. 1997).  
 
1.7.1.1   AKT 
 
In mammals, three isoforms of AKT (also referred to as protein kinase B =PKB) are 
encoded: AKT1, AKT2 and AKT3. All genes have greater than 85% sequence 
identity and share a common structure that consists of an N-terminal regulatory 
domain resembling the pleckstrin homology domain (Franke, Tartof et al. 1994), a 
kinase domain with serine-threonine specificity (Ahmed, Franke et al. 1993), and a C-
terminal region required for the induction and maintainance of its kinase activity 
(Chan, Rittenhouse et al. 1999). It is postulated that the three isoforms are 
functionally redundant (Franke 2000). 
 
The function of the PI3-kinase/AKT pathway in cell survival was first published in 
1995 by Yao and Cooper (Yao and Cooper 1995). The mechanism by which PI3-
kinase protects cells from programmed cell death involves the downstream activation 
of the protein kinase AKT. PtdIns(3,4)P2 and PtdIns(3,4,5)P3 lipids produced by PI3-
kinase are able to bind AKT through its pleckstrin homology domain and recruit the 
kinase to the plasma membrane.  
 
PKB/AKT is cytosolic and moves to the plasma membrane following PI3-kinase 
induction. At the membrane, Ser473 phosphorylation occurs through 
autophosphorylation or by PDK2. This region forms the docking site for PDK1, which 
binds and phosphorylates Thr308 (Persad, Attwell et al. 2001) (Figure 6 a).  
 
Another model of activation after growth factor stimulation of PI3-kinase implicates 
that the pleckstrin homology domain binds to PtdIns (3,4,5) P3 (PIP3), thus allowing 
PDK1 to phosphorylate Thr 308 (Andjelkovic, Alessi et al. 1997). Subsequent 
activation of AKT promotes autophosphorylation of Ser473 or PDK2 (Figure 6 b). 
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Figure 6:  Two models of AKT activation.  
In response to PI3 kinase induction, AKT isactivated through PDK1 and PDK2 
through phosphorylation of Thr308 and Ser473 residues (source: (Scheid and 
Woodgett 2001)) 
 
 
AKT has several downstream targets, which mediate cell survival. One of these 
targets is the Bcl-2 family member BAD, a pro-apoptotic protein, which is 
phosphorylated by AKT and thereby inhibiton of anti-apoptotic Bcl-2 molecules is 
exerted (Datta, Dudek et al. 1997).  
 
AKT also phosphorylates and thereby inactivates the death protease caspase-9. A 
decrease in apoptosis is caused by a reduced release of cytochrom c from the 
mitochondria, controlled by caspase-9 (Cardone, Roy et al. 1998).  
 
Increased proliferation after AKT activation is mediated by glycogen synthase kinase- 
3 (GSK-3), which is involved in cell cycle regulation. Inactivation of GSK-3 through 
AKT mediated phosphorylation leads to the stabilization of cyclin D1 (Diehl, Cheng et 
al. 1998). 
 
The metabolic function of AKT as a regulator of glucose metabolism is exerted by 
enhancing the uptake of glucose through an increase of endocytosis (Foster, Li et al. 
2001). Glucose uptake is enhanced through AKT, which also affects glucose 
transporters by an induction of GLUT1 and GLUT3 expression and a translocation of 
GLUT4 to the plasma membrane (Cong, Chen et al. 1997; Barthel, Okino et al. 
1999). The inactivation of GSK3 in turn leads to an AKT mediated increase in 
glycogen synthesis (Cross, Alessi et al. 1995). 
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Knock-out of AKT in mice led to a significant retardation in growth and to reduction of 
body weight (after AKT1 deletion) (Chen, Kim et al. 2001). Defects in the regulation 
of blood glucose levels following insulin stimulation (after AKT2 disruption) (Cho, 
Thorvaldsen et al. 2001) were detected in a mouse model.  
 
After the overexpression of activated AKT in mouse mammary glands, apoptosis was 
suppressed, and confirmed the requirement of AKT activity in apoptosis suppression 
(Hutchinson, Jin et al. 2001). It is suggested that AKT expression itself does not 
promote oncogenic transformation but it is required to promote anti-tumorigenic 
properties of PTEN (Moorehead, Fata et al. 2001; Stiles, Gilman et al. 2002). In a 
mouse model, the overexpression of IGF2 lead to a reduction of apoptosis, 
accompanied by sustained phosphorylation of AKT. 
 
Taken together, these results demonstrate that an increase in copy number or a 
molecular mutation of specific PI3-kinase genes leading to a ’gain of function’ results 
in an oncogenic transformation of many cell types. 
 
1.7.1.2   PTEN 
 
The phosphatase and tensin homolog deleted from chromosome 10 (PTEN), also 
known as MMAC1 (mutated in multiple advanced cancers), is a tumor suppressor 
gene that is mutated in a large number of cancers at high frequency. It is located on 
human chromosome 10q23, a genomic region that suffers loss of heterozygosity 
(LOH) in many human cancers (Cantley and Neel 1999). 
 
PTEN contains a protein tyrosine phosphatase (PTP) domain, which is able to 
dephosphorylate both tyrosine and serine/threonine residues. PIP3 is the main PTEN 
substrate. PTEN specifically cleaves the D3 phosphate produced by PI3-kinase 
activity (Maehama and Dixon 1998). Accumulation of PIP3 allows recruitment of 
AKT. In this context, the role of PTEN is to keep the levels of PIP3 low. Loss of PTEN 
function results in AKT hyperphosphorylation, leading to protection from apoptotic 
stimuli (Stambolic, Suzuki et al. 1998). It has to be emphasized that PTEN 
counteracts the cell survival of activated PI3-kinase or AKT co-expression. On the 
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other hand, activated PI3-kinase or AKT efficiently antagonize PTEN-mediated 
growth suppression. 
 
PTEN inactivation might also result in an increase in cell cycle progression mediated 
through GSK-3 inactivation, which leads to cyclin D1 stabilization. Reduced cyclin D1 
levels were revealed upon PTEN overexpression (Paramio, Navarro et al. 1999).  
 
Heterozygosity of PTEN leads to the development of a broad range of tumors derived 
from prostate, lung, brain, bladder, breast carcinomas (Steck, Pershouse et al. 1997; 
Teng, Hu et al. 1997). Heterozygous mice also developed signs of autoimmune 
diseases (Di Cristofano, Kotsi et al. 1999). Homozygous knockout led to embryonic 
lethality at day E 9.5 (Di Cristofano, Pesce et al. 1998; Suzuki, de la Pompa et al. 
1998). 
 
Several studies revealed a correlation between HCC and PTEN inactivation. Loss of 
a PTEN allele was identified in 20-30% of patients with HCC (Kawamura, Nagai et al. 
1999; Fujiwara, Hoon et al. 2000). Moreover, PTEN heterozygous mice exhibited 
neoplasms in the liver, suggesting that loss of PTEN may participate in liver 
carcinogenesis (Di Cristofano, Pesce et al. 1998). 
 
1.7.2  Impact of PTEN and pAKT on lipid and glucose  
  metabolism 
 
In mice, hepatocyte-specific PTEN deficiency resulted in non-alcoholic 
steatohepatitis (NASH) with triglyceride accumulation followed by liver cirrhosis and 
HCC (Horie, Suzuki et al. 2004). Upon inactivation of PTEN, the inversely correlated 
AKT pathway is stimulated.The promotion of chronic inflammation, resulting from NF-
кB translocation, might contribute to the onset of hepatitis (Watanabe, Horie et al. 
2007). 
 
Vinciguerra et al. showed that unsaturated free fatty acids decreased PTEN 
expression in HepG2 cells through activation of a signaling complex made of mTOR 
and translocation of NF-қB/p65 into the nucleus (Vinciguerra, Veyrat-Durebex et al. 
2008). 
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The interplay between lipid and glucose metabolism is mediated by the reciprocal 
relationship of substrate availability and consumption between liver and peripheral 
tissues (Abel, Smuts et al. 2001; Yang, Lin et al. 2001). Glucose homeostasis is, in 
part, regulated by the insulin-stimulated uptake of glucose in adipose tissue (Abel, 
Smuts et al. 2001; Minokoshi, Kahn et al. 2003). 
 
The failure in the insulin-like growth factor signaling cascade causes insulin 
resistance and metabolic disease, such as glucose intolerance, obesity and 
dyslipidemia. Upon receptor activation, PIP3 is generated, which in turn activates the 
AKT pathway. AKT controls diverse cellular substrates that are involved in glucose 
homeostasis (Brazil, Yang et al. 2004). Figure 7 illustrates the effects of AKT on 
glucose metabolism. 
 
 
 
Figure 7:  Regulation of glucose homeostasis by AKT.  
Enhancement of glucose uptake is mediated by affecting Glucose 
transporters (GLUT). Glycogen synthesis is stimulated by inhibition of 
glycogen synthase kinase-3 (GSK-3). Through a general increase in 
endocytosis glucose uptake is activated (source:(Kandel and Hay 
1999)) 
 
 
Liver-specific PTEN deficient mice display enhanced glycogenosis, demonstrated by 
an improved glucose clearance and lower glucose levels (Stiles, Wang et al. 2004). 
 
A hint for the role of PTEN in glucose metabolism was found after in vivo 
administration of antisense oligonucleotides, which improved hyperglycemia in 
diabetic mice (Butler, McKay et al. 2002). 
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All these data from the literature implicated a participation of IGF2 in glucose and 
lipid homeostasis and a set of experiments was performed to clarify the possible role 
of p62 in metabolic liver regulation due to its upregulation of IGF2 expression. 
 
1.8   RNA interference 
 
In 1998, Fire and Mello described a new technology based on specific gene silencing 
by double-stranded RNA (dsRNA) (Fire, Xu et al. 1998). Two types of small RNA 
molecules are central to RNA interference, micro RNAs (miRNA) and small 
interfering RNAs (siRNA). RNA interference is a defense mechanism protecting 
against the integration of foreign genetic material into the host genome. 
RNA interference is initiated by the enzyme Dicer which catalyses the cleavage of 
long dsRNA to 21-23 nt siRNA products (Bernstein, Caudy et al. 2001). One of the 
two strands is then introduced to the RISC protein complex and sequence-specific 
mRNA degradation is facilitated (Pellino and Sontheimer 2003) (Figure 8). 
 
 
 
Figure 8:  Mechanism of RNA interference.  
Cleavage of dsRNA by Dicer initiates genesilencing by generating 
siRNA molecules, by incorporation of a single strand of the RNA 
molecule into the RISC complex, post-transcriptional gene silencing is 
facilitated (source: http://www.borc.cn) 
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After specific gene silencing of the p62 mRNA in human hepatoma cell lines, 
investigations were made on the expression of IGF2 and H19. As the upregulation of 
both genes in p62 transgenic mice is accompanied by p62 overexpression, the 
question occurred whether the expression levels of IGF2 and H19 would decrease 
after siRNA-mediated mRNA degradation of p62. 
 
1.9   Mice 
 
Mice are a powerful tool for biological and medical researchers. After targeted 
changes of genes, occurring phenotypes can be reduced to a defined endogenous 
gene. Either overexpression of foreign genes or deletion of endogenous genes, as 
well as the introduction of point mutations, are possible strategies in gene targeting 
experiments. 
 
1.9.1   The tet-system 
 
The regulatory elements of the tetracycline-dependent expression systems were 
adapted from the tetracycline resistance of E. coli having its origin in the operon of 
transposon 10. In bacteria, the binding of the dimeric Tet-repressor (tetR) to the 
specific operon sequence (tetO) of the tetracycline promoter prevents transcription of 
the tetracycline resistance gene (tetA). Binding of tetracycline to the tetR is followed 
by a conformational change of the repressor, leading to its dissociation from the 
operon, thereby allowing transcription of the tetA gene (Hillen and Berens 1994). 
 
Gossen et al. generated a tetracycline transactivator (tTA) through the fusion of the 
tetracycline repressor with the Herpes simplex virus (Gossen and Bujard 1992). The 
tTA-dependent promoter consists of the human cytomegalovirus (CMV) ‘immediate 
early promoter’ (Boshart, Weber et al. 1985) and a tet-operator sequence (Baron and 
Bujard 2000).  
 
In the presence of tetracycline, or its analogon doxycycline (dox), tTA is prevented 
from binding to the promoter, whereas its absence results in the contrary (Figure 9). 
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Figure 9:  Gene regulation by the tet system.  
Tet-off: The TRE is located upstream of the minimal immediate early 
promoter of the cytomegalovirus (CMVmin) which is slient in the 
absence of activation. tTA binds to the TRE, thereby activating gene 
transcription in the absence of tetracycline.  
Tet-on: The Tet repressor reverses the protein response to 
tetracycline. As a result, transcription is activated in the presence of 
tetracycline (source: (Romano 2004)) 
 
 
1.9.2  p62 transgenic mice 
 
To elucidate the function of the hepatic p62 protein expression, p62 transgenic mice 
were generated in Prof. Eng M. Tan´ s group at the Scripps Research Institute (La 
Jolla, California, USA).  
 
The targeting vector construct was designed in a way that put the human p62 protein 
under control of the transrepressive responsive element cytomegaly virus (TRE-
CMVmin) promotor, ensuring that the livers of p62 transgenic mice did not express 
p62 mRNA due to repression of the promoter sequence within the targeting construct 
itself. Expression of the transgene was realized by crossing LT2 mice with p62 
transgenic mice. LT2 mice carry a cis-acting locus control-like element called liver 
enriched activator protein (LAP) under control of a tetracycline regulatory element 
(tTA) (Kistner, Gossen et al. 1996). The tTA activates the TRE-CMWmin promotor 
leading to its activation, followed by p62 mRNA expression. The LAP promotor 
accounts for an exclusive and liver-specific p62 expression. Moreover, the tTA allows 
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that overexpression of the p62 protein in the p62 x LT2 offspring is suppressed by 
the application of doxycycline to the drinking water (Kistner, Gossen et al. 1996) 
(Figure 10).  
 
 
 
Figure 10:  Generation of p62 transgenic mice and mechanism of doxycyclin-
 dependentregulation of hepatic p62 expression.  
No expression of p62 mRNA in livers of mice transgenic for p62 under 
TRE-CMV promotor control (upper panel). Liver-specific expression of 
p62 mRNA mediated through the tTA modulation of the TRE-CMV 
promotor in double-positive p62+/LT2+ mice (middle panel). 
Application of doxycycline inhibits transgene expression (lower panel). 
TRE-CMVmin: transrepressor responsive element cytomegaly virus; 
tTA: tetracycline transactivator; LAP: liver enriched activator protein; 
dox: doxycycline 
 
 
1.10  Aim of this work 
 
In order to investigate the functions of the hepatic expression of the tumor-associated 
autoantigen p62, transgenic mice were generated showing a liver-specific p62 
expression. 
 
Aim of this work was to elucidate phenotypic alterations induced by p62 
overexpression.
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2.  Methods  
 
2.1  Animals 
 
2.1.1  Animal welfare 
 
The animals were maintained on a standard 12 h light-dark-cycle, at a constant 
temperature (22±2 °C) and a relative humidity of 55 ±10% with free access to water 
and chow (Altromin, Lage, Germany). All animals received human care. The study 
was registered with the local animal welfare committee. The animals´ stock breeding 
was performed at the animal laboratory at the Institute of Genetics (Saarland 
University). 
For identification, animals received an ear tag with a three-digit number, at the same 
time a biopsy of the tail was taken for DNA isolation. 
 
2.1.2   Generation of p62 transgenic animals 
 
Mice were generated at the Scripps Research Institute in Prof. Eng M. Tan´ s group. 
Using the tetracycline gene transcription system allows a repression/ derepression of 
the liver-specific expression of the p62 transgene. A liver-specific Tet-system is 
established in a mouse model constructed by Kistner et al. (Kistner, Gossen et al. 
1996). Therefore, it was necessary to generate a mouse carrying the p62 DNA 
sequence under control of the TRE-CMV promoter. 
 
The first step was to insert the sequence of the TRE-CMVmin promotor and the 
human endogenous DNA sequence of p62 flanking exon 1 (ENSG00000073792 
(1862 bp), leading to an insert of 2248 bp in total, into the targeting vector pUHG10-
3/p-p62 (5548 bp).  
 
In a second step, embryonic stem cells were transfected with the targeting construct. 
Southern Blot experiments were performed to screen recombinant embryonic stem 
cells (data not shown). The recombinant clone was microinjected into pronuclei of 0.5 
day old oocytes, which were implanted into a pseudo-foster mother. Microinjection 
was performed onto B6D2 mice. The target integration into the genome occurs in a 
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randomized order. Germ-line transmission was confirmed by Southern Blot (data not 
shown). The offspring were chimeric. Male chimeric mice were mated with female 
mice. This led to mice being heterozygous for the transgene.  
 
As the expression the p62 transgene is repressed by the TRE-CMV promoter, it is 
necessary to cross them with LT2 mice, which carry a transactivator, leading to a 
depression of the promoter, thereby allowing p62 expression in the p62+/LT2+ 
offspring. 
 
Male and female p62 transgenic mice and their non-transgenic control littermates as 
well as the LT2 mice were obtained from Prof. Dr. Eng M. Tan, The Scripps 
Research Institute, La Jolla, USA. p62 transgenic mice show a liver-specific 
expression of the human p62 autoantigene.  
 
For SNuPE analysis, SD7 mice (carrying the mus spretus IGF2-H19 region, (Guenet, 
Nagamine et al. 1990) (courtesy provided by Prof. Dr. Jörn Walter, Institute of 
Genetics, Saarland University) were crossed with p62 transgenic mice. Male or 
female heterozygous LT2 mice were crossed with homozygous SD7 males or 
females to produce reciprocal progeny (LT2 x Mus spretus). F1 hybrids were mated 
to homozygous SD7 to produce heterozygous F2 offspring. For imprinting studies, 
p62 transgenic females were mated with F2 hybrid males. Mice, carrying no p62 
transgene but the heterozygous LT2/SD7 background served as control. The 
offspring carried single nucleotide primer polymorphisms (SNPs) for IGF2 and H19 
on chromosome 7. For the experiments, livers from both sexes were removed on 
postnatal days P0 and P16. 
 
Livers of 2.5 up to 10 week old animals were used for gene and protein expression 
analysis; for histological staining of paraffin- and cryo-embedded liver sections, as 
well as for SNuPE analysis.  
 
Instantly after organ removal, livers were placed in safe-lock Eppendorf tubes and 
frozen in liquid nitrogen. For long term storage, tissues were stored at -80°C. 
Paraffin-embedded livers were put into 4% formalin for 24 h straight after withdrawal. 
The processing and preparation of paraffin tissue blocks was kindly taken over by the 
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Institute of Pathology (University Hospital, Saarland University, Homburg/Saar, 
Germany).  
 
Isolated hepatocytes were examined in mRNA stability and caspase-3-like activity 
assays.  
 
2.1.3  Isolation of genomic DNA from mouse tails 
 
For genotyping of mice under the age of 3 weeks, a tail biopsy was taken during 
organ extraction. Elsewise, an approximately 0.5-1 cm biopsy from the tail of 3-week 
old mice was incubated in 100 µl water/10x Taq buffer (9:1) at 55°C for several hours 
while shaking. Addition of 1 µl Proteinase K (20 mg/ml) guaranteed degradation of 
proteins. After heat-inactivation of Proteinase K at 95°C for 15 min, 1 µl of the 
supernatant was used in the PCR reaction. 
 
2.2   Bacteria 
 
2.2.1  Preparation of competent bacteria 
 
A bacterial culture was incubated in 50 ml LB medium o. n. at 37° C in a shaking 
incubator. The next morning, 1 ml of this culture was transferred into 100 ml LB 
medium and allowed to grow up to an OD600 of 0.3. Subsequent, cells were cooled 
down to 4°C and centrifuged for 5 min at 4,000 x g.  The pellet was resuspended in 
50 ml 50 mM CaCl2 and stored on ice for 20 min. After an additional centrifugation 
step for 5 min at 4,000 x g, the pellet was resuspended in 10 ml of a solution of CaCl2 
containing 15% Glycerol. Cells were aliquoted, frozen in liquid nitrogen and stored at 
-80°C. 
 
2.2.2  Transformation of plasmid DNA in competent bacteria 
 
5 ng of the transforming plasmid were mixed with an aliquot of the chemically 
competent bacteria. After incubation on ice for 30 min, heatshock was performed at 
42°C for 30 sec, subsequently followed by the addit ion of 1 ml LB medium. Bacteria 
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were shaken for 30 min in at 37°C in an incubator, before they were plated onto a LB 
agar plate. 
 
2.2.3 Isolation of plasmid DNA  
 
In order to allow absolute quantification in real-time RT-PCR, fragments of the target 
genes cloned into the pGEMTeasy® (Promega, Mannheim, Germany) vector were 
used as a standard. A 1:10 dilution series of the plasmid DNA was prepared, starting 
at a concentration of 20 attomol/µl (S1). Standards S1-S7 were run on each PCR 
plate in duplicates. 
 
The plasmids were amplified in competent bacteria (XL-1 Blue) and isolation was 
carried out with the MiniPrep kit (Qiagen, Hilden, Germany). 
 
7 ml of LB broth medium containing 14 µl ampicillin (50 µg/ml stock solution) were 
inoculated with a single clone of the designated colony and incubated at 37°C and 
225 rpm o. n. The bacterial culture was transferred into a centrifuge tube and spun 
down at 4,000 x g for 10 min. The supernatant was discarded and the pellet was 
processed using the QIAprep Miniprep Kit (Qiagen, Hilden, Germany). To dissolve 
the plasmid DNA, 50 µl TE buffer was added to the tube. 
 
2.2.4  Determination of DNA concentration 
 
The concentration of the nucleic acids was determined by photometric analysis. An 
OD260 of 1 corresponds to 50 µg/ml dsDNA. The quality of the isolation was verified 
by measuring the absorption at 280 nm, corresponding to the absorption maximum of 
proteins. The ratio of the two absorption values gives information on the purity of the 
sample, with optimal values ranging between 1.8 and 1.95. 
 
2.3  Agarose gel electrophoresis 
 
Agarose gel electrophoresis is a method to separate DNA molecules of 0.1 up to 25 
kb by size. In an electric field, the negatively charged DNA molecules migrate 
through the agarose matrix towards the anode. DNA molecules are separated 
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according to their size, i. e. the bigger the DNA fragment, the slower it runs through 
the gel.  
 
After boiling the agarose in 1x TBE in a microwave, the solution was stirred while 
cooling down below 56°C before 0.1-0.5 µg/ml ethidi um bromide (3,8-diamino-5-
ethyl-6-phenylphenanthridinium bromide) was added for later visualisation.  
 
The dye intercalates into base pairs (inclusion within a distance of 10 bp) of the DNA 
molecule. For detection, the gel is exposed to UV light. Typically, DNA fragments 
appear as luminous bands whereas areas without nucleic acids are dark. For size 
determination, a DNA-ladder can be applied onto the gel.  
 
In this work, a 1 kb-ladder from Invitrogen (Karlsruhe, Germany) as well as a 50 bp-
ladder (Amersham, GE-Healthcare, Munich, Germany) in a amount of 5 µl were used 
(supplement 7.7). 
 
DNA fragments obtained from PCR reactions were separated in 1.5% agarose gels 
in 1x TBE buffer. For the detection of polymorphisms, 2% agarose gels were 
employed. 10 µl of the PCR product were mixed in a ratio of 1:6 with 6x dye, 
containing bromophenol blue (migrates at the same rate as the 500 bp DNA 
fragment) and xylene cyanol (migrates at about the same rate as the 4,000 bp DNA 
fragment) as indicators that mark the process of gel electrophoresis. The mix was 
applied onto the gel and the run was carried out in a gel chamber with 1x TBE at 100 
V for ~30 min. 
 
2.4  PCR (Polymerase Chain Reaction) 
 
PCR is an in vitro technique for the replication of DNA segments enframed by two 
sequence-specific oligonucleotides (primers) (Mullis and Faloona 1987). In a chain 
reaction, a thermally stable DNA polymerase amplifies the target DNA through the 
assembly of nucleotides to the primer sequences along the single-stranded, 
denatured DNA matrix. New DNA strands were synthesised. As the newly 
synthesised DNA strands serve as templates in each cycle, the copy numbers 
increase exponentially (Cornel 2008). 
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A basic PCR set up requires several components and reagents: 
 
-  the DNA matrix (template) that contains the DNA region to be amplified 
- two oligonucleotides, i. e. short, single-stranded DNA molecules, that are 
 complementary to the 5´- or 3´-end of the DNA-strain  
- desoxynucleotidetriphosphates (dNTPs), the building blocks that are 
 incorporated during the DNA synthesis  
- DNA polymerase, usually Taq polymerase (thermally stable), for the 
 synthesis of new DNA double strands 
- polymerase buffer and Mg++ ions (important for incorporation of dNTPs, 
 required for optimal polymerase activity and stability) 
 
The PCR usually consists of a series of 25 to 40 repeated temperature cycles, each 
cycle typically consists of 2-3 discrete temperature steps. 
 
- Denaturation step, causes melting of the doublestrand (ds), performed at 93-
 95°C 
- Annealing step, single-stranded primers bind to the single-stranded template
 at 56-62°C. The polymerase binds to the primer-tem plate hybrid and begins
 DNA synthesis.  
- Extension step at 72°C, the DNA polymerase synthesizes a new  DNA strand 
 by adding dNTPs to the template in 5’- to 3’-direction. 
 
In this work, PCR was performed for: 
 
- genotyping of transgenic mice 
- generation of DNA fragments, serving as templates in the SNuPE analyses 
- controlling the quality of cDNA after syntheses 
- quantification of mRNA expression. 
 
Used DNA matrices were either genomic DNA from mouse tails or cDNA from liver 
tissues or isolated hepatocytes.  
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PCR protocol: 
 
The PCR reaction was carried out in a Px2 thermal cycler (Thermo Electron, 
Karlsruhe, Germany). Taq polymerase from GenScript (USA) was used as thermally 
stable DNA polymerase. Different PCR protocols were performed. 
 
dNTPs (GenScript)   1.25 mM 
dNTP 10 mM (stock)       125 µl 
H2O        ad    1,000 µl 
 
Taq Polymerase 5 U/µl 
 
primer A (10 pmol/µl)    1.0 µl 
primer B (10 pmol/µl)    1.0 µl 
dNTPs (1.25 mM)     2.0 µl 
10 x PCR buffer     2.0 µl 
polymerase (5 U/µl)    0.5 µl 
template DNA     1.0 µl 
H2O         ad 20.0 µl 
 
PCR program for genotyping of p62 mice: 
 
95°C   5 min 
95°C   30 sec 
56°C   30 sec 
72°C   30 sec (35x) 
72°C   5 min 
 
An aliquot of the PCR reaction (10 µl) was applied onto an agarose gel and 
separated electrophoretically. Bands in the ethidium-bromide containing gel were 
visualized under UV-light. 
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2.5   Reverse transcription 
 
RNA is isolated from the cells or tissue of interest and transcribed into a copy I DNA 
by the enzyme reverse transcriptase (RT). 
 
Three different enzymatic activities are combined in the RT enzyme: 
- RNA-dependent DNA polymerase (reverse transcription) 
- ribonuclease (RNAseH, degragation of RNA in RNA/DNA hybrids) 
- DNA-dependent DNA polymerase. 
 
The enzyme RT was originally isolated from retroviruses. The combination of the 
three functions allows in vivo transcription of the retroviral RNA-genome into a ds- 
DNA. In vitro, only the first and third function is necessary for the synthesis of the 
cDNA. Amplification starts at the 3´-hydroxyl end. 
 
Transcription of RNA into cDNA can be done with three different primers (Sellner 
1992): 
- random primer mix (hexanucleotide primer mix): mixture of short (6 bp long) 
 primers, showing every possible sequence 
- oligo (dT) primer mix: binds to the 3´-poly A-tail of mRNA 
- sequence specific primers. 
 
For the experiments described here, either random primers (used for templates from 
mouse tissues or from mouse derived tissue culture cells) or oligo (dT) primers (used 
for templates from human tissue culture cells) were applied. 
Afterwards, the cDNA served either as template in the real time PCR using 
sequence-specific primers or in the SNuPE-HPLC analysis. 
 
Performance: 
 
1) RNA preparation 
 
The one-step RNA isolation method is based on the GITC (guanidium-isothiocyanat) 
method described by Chomczynski and Sacchi (Chomczynski and Sacchi 1987). 
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Trizol is a monophasic solution from phenol and GITC, stabilizing RNA, whereas 
cells and soluble cell components are lysed. GITC is a strong inhibitor of 
ribonucleases. 
 
1a)  Preparation of liver tissue from mice 
 
Liver tissue was homogenized in 0.3 ml Trizol (Qiagen, Hilden, Germany) and 
subsequently filled up to 1.0 ml Trizol in an Eppendorf tube. After addition of 250 µl 
Chloroform and shaking, samples were incubated for 3 min at RT.  
 
1b)  Preparation from tissue culture cells 
 
Cells from 6-well plates were harvested by removing the tissue culture medium and 
washing twice with 1x PBS. Subsequently, 300 µl Trizol was added and cells were 
scraped off the bottom of the well with a cell scraper, before the Trizol solution 
containing the RNA was transferred into an Eppendorf tube. After addition of 63 µl 
Chloroform and shaking, samples were incubated for 3 min at RT. 
 
The RNA is now in the upper phase of the solution due to the pH value. By 
separating and spiking of the upper phase, RNA was precipitated with 1/1 volume of 
isopropanol. The RNA precipitates were washed in 70% ethanol and finally dissolved 
in 15 µl or 30 µl DEPC water. 
 
2) DNase treatment of isolated RNA 
 
To ensure exclusive amplification of cDNA during PCR, it is necessary to eliminate 
contaminations of sample RNA with genomic DNA. Ambion DNA free kit (Applied 
Biosystems, Darmstadt, Germany) was used for DNAse treatment: 1/10 volume of 
10x DNAse I buffer and 1 µl DNAse I were added to the RNA and incubated for 45 
min at 37°C. Subsequently, 1/10 volume of DNAse ina ctivating reagent was added. 
After centrifugation, the supernatant was transferred into a fresh Eppendorf tube. 
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3) Determination of the amount and quality of RNA in a photometric assay 
 
RNA concentration was determined at a wavelength of 260 nm in a photometer 
(BioMate3, Thermo Electron Corporation, Karlsruhe, Germany). 40 µg RNA/ml 
corresponds to an optical density (OD260) of 1. 
 
Proteins have an absorption maximum at 280 nm. 1.8 mg/ml protein corresponds to 
an OD280 of 1. 
 
A ratio of 1.8 to 1.95 (for DNA), and of 1.9 to 2.0 (for RNA) of the measurements at 
260 and 280 nm suggest a high purity of the sample. Lower values suggest protein or 
phenol contamination, higher values result from denatured DNA or contamination of 
genomic DNA in RNA samples.  
 
4) Reverse transcription 
 
The first step consists of the denaturation of RNA for 10 min at 70°C. Either random 
or oligo (dT) primers are now able to bind to the single-stranded template. cDNA 
corresponding the RNA matrix is synthesized by the enzyme RT. Afterwards, cDNA 
can be used to perform PCR experiments. All steps were prepared on ice. 
 
The following RT(+) approach (total volume: 10 µl) was used: 
 
10x RT buffer      2.0 µl 
25x dNTP mix (100 mM)     0.8 µl 
MultiScribeTM Reverse Transcriptase (50 U/µl)  1.0 µl 
Rnase Inhibitor (10 U/µl)     1.0 µl 
Nuclease-free H2O      3.2 µl 
10x RT random primers     2.0 µl or 
oligo (dT) primers (10 µM)     2.0 µl 
 
The RT(-) approach without enzyme was carried out with the same samples in order 
to check for leftovers of genomic DNA in a later β-actin PCR. 
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1 µg RNA in a total volume of 10 µl was reverse-transcribed. Incubation was done in 
a Px2 thermal cycler (Thermo Electron, Karlsruhe Germany). 
 
The following RT program was used: 
 
Step 1    25 min at 10°C 
Step 2  120 min at 37°C 
Step 3      5 sec at 85°C 
 
followed by instant cooling of the cDNA samples to 4°C. The samples were diluted 
1:5 to a final volume of 100 µl. cDNA was stored at -20°C, for long time storage at  
-80°C. 
 
5) Alu-PCR 
 
Using primers specific for repetitive sequences in the human genome (‘Alu’ 
elements), it is possible to test on genomic DNA residues in RNA samples. Did 
separation of samples by gel electrophoresis reveal no amplification products, the 
RNA quality was verified and RNA could be used for reverse transcription. 
 
The following approach was set up: 
 
10x Taq buffer      2.5 µl 
10 mM dNTP mix       2.0 µl 
Taq polymerase (5 U/µl)     0.5 µl 
primer AS1 (50 µM)     0.5 µl 
MgCl2 (50 mM)      1.25 µl 
template RNA      100 ng  
H2O              ad 25.0 µl 
 
As positive reaction, 5 ng genomic DNA from THP-1 cells (kindly provided by Jessica 
Hoppstädter, Pharmaceutical Biology, Saarland University) was used. The Alu PCR 
was carried out in a Px2 thermal cycler (Thermo Electron, Karlsruhe, Germany). 
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Alu PCR program: 
 
94°C    5 min 
94°C     1 min 
56°C    1 min 
72°C    1 min (30x) 
72°C     10 min 
 
Amplification products appear as several diffuse bands of heterogenous size on 
agarose gels. 
 
6) ß-actin PCR 
 
To assure for RNA sample quality, a β-actin PCR was performed with the RT (-) 
preparation. In the case of detection of an amplification product after gel 
electrophoresis, the band must result from genomic DNA contaminants because no 
reverse transcriptase enzyme is added to the RT (-) mix. 
 
The reaction included: 
 
10x Taq buffer      3.0 µl 
10 mM dNTP mix       2.4 µl 
Taq polymerase (5 U/µl)     0.5 µl 
primer A (10 pmol/µl)     1.0 µl 
primer B (10 pmol/µl)     1.0 µl 
template RT(-)      1.5 µl  
H2O            ad 30.0 µl 
 
The β-actin PCR was run in a PX2 thermal cycler.  
 
 Methods 42 
PCR program: 
 
94°C    3 min 
94°C    30 sec 
62°C    1 min 
72°C    1 min (30x) 
72°C     5 min 
 
10 µl of the amplification product were separated on an agarose gel. RNA samples 
were used in the reverse transcriptase reaction when no bands could be visualized. 
 
2.6   Real-time quantitative RT-PCR 
 
For detection and simultaneous quantification of gene expression patterns, real-time 
RT-PCR (Q-PCR) is a widely-used technique. PCR based methods have the 
advantage of being fast and highly sensitive.  
 
Real-time polymerase chain reaction is based on the use of fluorescence reporter 
molecules to observe product amplification during each cycle of the PCR. 
Fluorescence signal intensity increases proportionally to the amount of amplification 
product. 
 
The threshold cycle (Ct), which represents the PCR cycle at which an increase in 
reporter fluorescence above background is first detected, is determined in the real 
time assay. The Ct value inversely correlates with the initial amount of template, i.e. 
the more is in the reaction tube, the earlier the Ct value can be measured. Moreover, 
the Ct value defines the exponential phase of the PCR reaction, within which the 
extrapolation to the initial amount can be done. 
 
Detection can be verified with different methods (Figure 11): 
- unspecific intercalation of fluorescent dyes (e.g. SYBR® green) into the DNA 
- specific detection using fluorescent probes (TaqMan®, molecular beacons, 
 hybridised probes). 
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Figure 11:  Principles of real-time RT-PCR techniques.  
a)  SYBR Green I technique. SYBR Green I fluorescence is enormously 
increased upon binding to double-stranded DNA.  
b)  Hydrolysis probe technique. The hydrolysis probe is conjugated with a 
quencher fluorochrome, which absorbs the fluorescence of the 
reporter fluorochrome as long as the probe is intact. Upon 
amplification of the target sequence, the hydrolysis probe is displaced 
and hydrolyzed by the Taq polymerase. Due to the separation of the 
reporter and quencher fluorochrome, the increase in fluorescence 
becomes detectable. 
(http://www.nature.com/leu/journal/v17/n6/fig_tab/2402922f1.html) 
 
 
Within this work, SYBR® green was used for all experiments performed on cDNAs 
derived from human material, whereas TaqMan® probes, carrying a fluorescent dye 
(FAM) at the 5´-end, were used for cDNAs derived from mouse material. 
 
SYBR® green detection is based on the principle that the DNA-binding dye anneals to 
all ds-DNA in the PCR reaction, causing a fluorescence signal. An increase in DNA 
product during PCR leads to an increase in fluorescence intensity and is measured at 
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each cycle, thus allowing DNA concentrations to be quantified. As ds-binding dyes 
bind to all ds-DNA templates, it is necessary to perform a melting curve analysis after 
the end of the PCR reaction to distinguish specific from non-specific products. 
 
For the detection using fluorescent probes, TaqMan® probes carry a fluorescent 
reporter at one end and a quencher of fluorescence at the opposite end. The close 
proximity of the reporter to the quencher prevents detection of its fluorescence. Both 
primers and probe anneal to the DNA target. Polymerisation of the new strain starts 
from the primers, and once the polymerase reaches the probe, breakdown of the 
probe due to the 5’- to 3’-exonuclease activity of the Taq polymerase decreases the 
reporter-quencher proximity and thus allows detection of fluorescence emission. An 
increase in the product targeted by the reporter probe at each PCR cycle causes a 
proportional increase in fluorescence.  
 
The two following approaches were pipetted on ice: 
 
a) dNTPs (1.25 mM)      2.0 µl 
10x PCR buffer      2.5 µl 
primer A (10 pmol/µl)     1.25 µl 
primer B (10 pmol/µl)     1.25 µl 
Taq polymerase (5 U/µl)    0.5 µl 
MgCl2 (50 mM)      x µl 
TaqMan probe (1 pmol/µl)    x µl 
template DNA     5.0 µl 
H2O           ad 25.0 µl 
 
Amounts of the TaqMan® probes were 1.5 to 2.5 pmol. Concentrations for MgCl2 
differed from 3 to 5 mM depending on the approach (supplement 7.3). 
 
b) template DNA        5.0 µl 
 Dynamo Flash SYBR®green qPCR kit   12.5 µl 
 H2O             ad 25.0 µl 
 
Either cDNA or plasmid DNA served as template DNA in the PCR reaction. 
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PCR program for TaqMan® probe detection: 
95°C        8 min 
95°C        15 sec 
60°C        15 sec 
72°C        15 sec (40x- 45x) 
72°C        3 min 
 
PCR program for SYBR®green detection: 
95°C       x min 
94°C       x sec 
60°C       x sec 
72°C       x sec (40x) 
55°C-95°C      7 sec in 0.5 temperature steps 
 
Initial denaturing step varied from 5 to 10 min. Denaturing at 94°C lasted between 10 
to 30 sec. Annealing and extension required 15 to 30 sec. Details regarding the 
cycling conditions are found in the supplement 7.3 and 7.4. 
 
Real time PCR reactions were performed in an iQ5 cycler (BioRad, Munich, 
Germany). Each sample was run in duplicate or triplicate. 
 
Quantification 
 
Relative concentrations of DNA present during the exponential phase of the reaction 
are determined by plotting relative fluorescent units against cycle number showing an 
exponential curve. A threshold value for detection of fluorescence above background 
is determined by the software, called Ct. Since the quantity of DNA doubles every 
cycle during the exponential phase, relative amounts of DNA can be calculated, e.g. 
a sample whose Ct is 4 cycles earlier than another´ s has 24 = 16 times more 
template. 
 
Amounts of mRNA are determined by comparing the results to a standard curve 
produced by serial dilutions of a plasmid DNA. To accurately quantify gene 
expression, the measured amount of mRNA from the gene of interest is divided by 
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the amount of RNA from a housekeeping gene measured in the same sample to 
normalise for variations in the amount and quality between different samples. 
Providing unregulated expression of the reference gene transcript, normalization 
permits accurate comparison of the gene expression of interest (Bustin 2000). 
 
2.7   SNuPE analysis 
 
PCRs were performed in a 30 µl reaction volume on cDNA. 
 
The reaction included: 
10x Taq buffer      3.0 µl 
10 mM dNTP mix       2.4 µl 
Taq polymerase (5 U/µl)     0.5 µl 
primer A (10 pmol/µl)     1.0 µl 
primer B (10 pmol/µl)     1.0 µl 
template cDNA      1.5 µl  
 
The IGF2 and H19 PCRs were run in a Px2 thermal cycler.  
 
PCR program for IGF2: 
 
95°C    5 min 
94°C    30 sec 
60°C    1 min 
72°C    1 min (32x) 
72°C     5 min 
 
PCR program for H19: 
95°C    5 min 
94°C    1 min 
60°C    1 min 
72°C    30 sec (35x) 
72°C     5 min 
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Successful PCR was checked by loading 5 µl of the reaction on a 1.5% agarose gel. 
 
The following experimental procedure was kindly performed by Dr. Sascha Tierling, 
Institute of Genetics, Saarland University. 
 
SNuPE primers were placed immediately adjacent to the polymorphic sites (IGF2: C: 
T SNP at position nt 1678 in the mRNA, H19: C: T SNP at position nt 2437 in the 
mRNA. 5 µl of PCR products were purified using an Exonuclease I/SAP mix (1U/9U, 
USB) for 30 min at 37° C followed by a 15 min inact ivation step at 80° C. 14 µl primer 
extension mastermix was added and SNuPE reaction was performed. 
 
SNuPE program: 
 
96° C    2 min 
96° C    20 sec (50x) 
60° C    2 min 
 
Obtained products were loaded on a DNASepTM (Transgenomic) column and 
separated at 50°C applying an acetonitrile gradient  by continuously mixing buffer A 
and buffer B: IGF2 22-32% buffer B for 15 min, H19 17-30% buffer B for 15 min. The 
allele-specific expression index was determined by measuring the peak heights and 
calculating the ratio hI/ [hI + h(T)]. 
 
2.8  Western Blot  
 
PTEN, pAKT and p62 protein levels were investigated by Western Blot analysis. 
 
Western Blot is a technique used to identify and quantify specific proteins. Protein 
lysates are separated using denaturating SDS gel electrophoresis, allowing protein 
segregation according to the size.  
 
After immobilisation of the proteins on a PVDF membrane, free protein-binding sites 
of the membrane have to be blocked by proteins, which cannot be detected by the 
antibody. This is necessary to eliminate unspecific binding of the antibody. To detect 
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specific binding of the antibody to the epitope of the antigene, species-specific 
antibodies conjugated to a fluorescent dye are used. 
 
2.8.1   Preparation of protein extracts from mouse liver tissue 
 
All work was performed on ice. 100 mg liver tissue were homogenised in 1 ml lysis 
buffer. After centrifugation (15 min, 4°C, 14,000 g) proteins remain in the 
supernatant.  
 
After determination of protein concentrations by the method of Bradford (BioRad, 
Munich, Germany), each lysate was mixed with 1:3 with Roti®-Load sample buffer 
(Carl Roth, Karlsruhe, Germany) before denaturation was performed at 95°C for 5 
min.  
 
2.8.2   Preparation of protein extracts from isolated mouse hepatocytes
  and hepatoma cell lines  
 
Untreated or treated cells grown in tissue- culture plates were harvested by removing 
the cell culture medium before adding 100 µl lysis buffer. Cells were scraped off and 
the lysates were transferred to Eppendorf tubes. After centrifugation, the 
homogenates were treated as described above 2.8.1. 
 
2.8.3    Determination of protein concentration using the Bradford assay 
 
This is a spectroscopic method to measure protein concentrations based on a 
change in colour of the dye coomassie. After protein binding, the absorbance shifts to 
595 nm due to coomassie red changes into coomassie blue. 
 
Out of a BSA stock solution, a dilution series (2.5/5.0/7.5/10/15/20/25 µg/ml) was 
made according to the following scheme: 
 
1.0 g BSA was dissolved in 100 ml H2O. 10 ml of this solution was diluted in 90 ml 
H2O to a concentration of 1 mg/ml (=stock). Aliquots of the dilution series were stored 
at -20°C. 
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Measurements were performed in a SunriseTM multiplate reader (Tecan, Crailsheim, 
Germany) in 96-well tissue culture plates. 10 µl protein or BSA standard was mixed 
with 190 µl Bradford reagent (1:5) and detected in triplicate. Protein concentrations 
were assessed compared to the BSA standard protein curve. 
 
2.8.4   SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Due to negative charging of samples, migration through the gel towards the anode 
simply corresponds to the molecular weight of the proteins. Equal amounts of protein 
were loaded and separated by SDS-PAGE (Mini Protean chamber, BioRad, Munich, 
Germany). Proteins were stacked at 110 V for 10 min and resolved at 130 V for 60 
min. 
 
2.8.5   Protein transfer onto PVDF membranes  
 
The blotting membrane (Immobilon PVDF-FL, Millipore, Schwalbach/Taunus, 
Germany) was cut to the size of the gel and equilibrated in methanol and 
subsequently in transfer buffer. 
 
For the transfer set-up, a fibrous web and three pieces of moisturised filter paper 
were put on the cathode plate. On top, the gel and the membrane followed by 
another three pieces of moisturised filter paper and a fibrous web, everything forming 
an air bubble free stack, were placed (Figure 12). With the membrane directing 
towards the anode, blotting was performed at 170 mA for 150 min.  
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Figure 12:  Western Blot setup.  
Schematic representation of the assembly for the transfer of proteins 
onto a PVDF membrane. (www.bme.gatech.edu) 
 
 
After the transfer, the membrane was incubated in Rockland Blocking Buffer (RBB) 
(Biomol, Hamburg, Germany) at room temperature for 60 min. The blocked 
membrane was incubated either at 4°C over night or at room temperature (10-60 
min) with the adequate primary antibody in a dilution of 1:1,000 in RBB. Proceeding 
three washing steps in PBST, the specific secondary antibody was incubated for 30-
60 min at room temperature under exclusion of light. After additional washing steps 
with PBST (2 x 20 min) and PBS (2 x 10 min), detection of immunoreactive bands 
was visualized by the Odyssey Infrared Imager (Licor Biosciences, Bad Homburg, 
Germany). To exclude loading differences, the blots were also probed with an 
antibody against the housekeeping protein α-tubulin (Sigma Aldrich, Munich, 
Germany). 
 
To distinguish between protein expressions in lysates gained from control versus 
transgenic animals, samples were (semi-) quantified using the Odyssey software 
tool. The integrated intensity values for all samples were normalized to a 
housekeeping protein to adjust for uncontrolled variability.  
 
Antibodies specific to phosphoAKT (Ser473), PTEN (both New England Biolabs, 
Frankfurt a. M., Germany), and anti α-tubulin (Sigma, Thermo Fisher Scientific, 
Karlsruhe, Germany) were incubated overnight at 4 °C in Odyssey Blocking buffer 
(LI-COR biosciences). Dilution factors can be found in the supplement 7.5. 
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For visualization of proteins with the Odyssey Infrared Imaging System (LI-COR 
Biosciences, Bad Homburg, Germany) membranes were blocked in Rockland 
Blocking buffer (Biomol). After washing, membranes were incubated with an 
IRdye680 conjugated goat anti-rabbit IgG secondary antibody (in case of PTEN and 
phosphoAKT detection) or with an IRdye800 CW conjugated goat anti-mouse 
antibody (in case of tubulin detection) in a 1/5,000 dilution in Odyssey Blocking Buffer 
(LI-COR Biosciences, Biomol, Hamburg, Germany). Secondary antibodies, goat anti-
rabbit IRdye®680 and goat anti-mouse IRdye®800 CW, were purchased from 
Rockland (Biomol, Hamburg, Germany). After a subsequent washing step, proteins 
were detected and quantified with the Odyssey Infrared Imaging System. 
 
2.9   Cell culture 
 
Since cells were cultured under sterile conditions, all solutions were autoclaved or 
sterile filtered. 
 
The human hepatocellular liver carcinoma cell lines HepG2, HUH7 and Alexander 
cells were originally isolated from male patients of different age and ethnicity, all 
suffering from primary liver carcinoma (Alexander, Bey et al. 1976; Aden, Fogel et al. 
1979; Nakabayashi, Taketa et al. 1982). HepG2 and HUH7 cells show a higher 
expression of IGF2 compared to Alexander cells (Desbois-Mouthon, Baron et al. 
2009). For H19 RNA, with which IGF2 is epigenetically closely related, low levels are 
reported in HepG2 and HUH7 (Banet, Bibi et al. 2000). Abnormal p53 gene 
expression is a frequent event associated with HCC. Alexander cells display greatly 
reduced p53 mRNA and protein expression levels in comparison to HepG2 and 
HUH7 cells (Bressac, Galvin et al. 1990). All three liver carcinoma cell lines were 
cultured in a humidified incubator at 37°C with 5% CO2 in RPMI-1640 (PAA, Cölbe, 
Germany) containing 10% FCS gold (PAA, Cölbe, Germany), 2 mM L-glutamine 
(PAA, Cölbe, Germany) and 1% Penicillin/Streptomycin (P/S, PAA, Cölbe, Germany) 
to prevent bacterial contamination. Cultures at ~80% confluence were routinely 
passaged and subcultured to 80-90% confluence before any experimental 
procedures. 
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For thawing of cells, 8 ml RPMI medium was provided in a 25 cm2 cell culture flask 
(Greiner Bio-one, Frickenhausen, Germany) before one cryovial of the appropriate 
cell line was added. Cultures at ~80% confluence were routinely split in a ratio of 1:3. 
Therefore, culture medium was removed and cells were washed with 1x PBS to 
remove dead cells, cell debris and to eliminate medium leftovers which would 
interfere with trypsin treatment. Approximately 5 ml 1x Trypsin/EDTA was added and 
cells were incubated at 37°C with 5% CO 2 until the cells were detached from the 
bottom of the flask. To inhibit trypsin activity, ~15 ml RPMI medium was added and 
cells were subsequently transferred into a Falcon tube to spin them down at 50 x g. 
After careful resuspension and separation of cell clusters, cells were plated to a new 
flask.  
 
From early passages, cryostocks were generated by adding 20% DMSO to the RPMI 
medium. Cryovials, containing 1 ml cell suspension, were stored at -20°C and -80°C 
before they were frozen in liquid nitrogen for long-term storage. 
 
2.9.1  Determination of cell amount and cell viability 
 
Cell amount and viability were determined in an improved Neubauer counting 
chamber using trypan blue. As the dye penetrates through the cell membrane of 
dead cells, they can be distinguished from living cells. 
A 1:10 dilution of cells was mixed 1:1 with trypan blue. The cell suspension was 
inserted into the chamber before counting of cells within one square of the grid. 
 
2.9.2   Determination of living cells 
 
amount of cells x10,000 x dilution factor of cells = amount of living cells 
 
In an improved Neubauer counting chamber, the total number of cells per ml can be 
defined after counting one corner square by multiplying the total number of cells 
found in the grid by 104 (Figure 13).  
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Figure 13:  Improved Neubauer counting chamber. 
(www.nexcelom.com) 
 
 
2.9.3  Cell viability assay 
 
Toxic effects of INTERFERinTM were tested in the colorimetric MTT assay. Yellow 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced to 
purple formazan only by living cells (Mosmann 1983). 
 
200 µl RPMI medium containing 1.5 x 104 cells were plated in a 96-well plate and 
incubated for 24 h. After removement of medium, cells were incubated for 20 h with 
different dilutions of the transfection reagent in RPMI. The supernatant was replaced 
by 150 µl MTT solution (0.5 mg/ml). After 2 h incubation at 37°C with 5% CO 2, 100 µl 
of the MTT solution was removed and cells were lysed by addition of 200 µl of the 
lysis reagent dimethylsulfoxide (DMSO). After gentle shaking, the absorption was 
measured in an ELISA reader at 550 nm.  
 
2.9.4   Treatment of human hepatocellular carcinoma cell lines with 
  siRNA  
 
For transfection experiments cells were harvested from a flask and transferred into a 
12-well cell culture plate (Greiner Bio-One, Frickenhausen, Germany). Transfection 
was carried out with cells approximately 50% confluent. The high-purity, full-length 
siRNA against p62 used in this work was purchased from Qiagen (Hilden, Germany). 
As a negative control, the random siRNA ‘siGENOME non-targeting siRNA #2’ 
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(Dharmacon, Thermo Fisher Scientific, Karlsruhe, Germany) was used. Sequences 
of both siRNAs used within this work are given in supplement chapter 7.6. 1 nM 
siRNA was determined to be the optimal working concentration for efficiently knock-
down gene expression, avoiding ‘off-target’ effects. 
 
2.9.5  Preparation of siRNA  
 
Before using the siRNA for the first time, it was necessary to add 250 µl siRNA 
suspension buffer (Qiagen, Hilden, Germany) to the lyophilisate of siRNA to obtain a 
20 µM solution (= stock). After incubation at 95°C for 1 min and at 37°C for 1 hour, 
suspension buffer was added to produce a 2 µM solution of siRNA. Aliquots of 1 ml 
of the 2 µM solution were stored at -20°C until use . 
 
2.9.6   Transfection reagent 
 
For siRNA delivery into the cell, INTERFERinTM (Biomol, Hamburg, Germany) was 
used. INTERFERinTM consists of a cationic lipid complex, able to bind negatively 
charged siRNA. The resulting complex overcomes the cell membrane via 
endocytosis. In the cytoplasm siRNA is released from the siRNA-INTERFERin 
complex and can mediate RNA interference (RNAi). INTERFERinTM was stored at 
4°C. 
 
2.9.7   Transfection of human hepatocellular carcinoma cell lines 
 
Experiments were carried out in 12-well cell culture plates using the reverse 
transfection method. In reverse transfections, the siRNA-transfection reagent 
complexes are prepared inside the wells. Thereafter, cells and medium are added 
(Figure 14).  
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Figure 14:  Workflow comparison of transfections formats. 
(www.dharmacon.com/docs/RTF_Application_Note.pdf) 
 
 
A volume of 2 µl INTERFERinTM/well was chosen due to low cytotoxicity determined 
in the MTT assay. 2 µl INTERFERinTM and 0.125 µl siRNA (=1 nM/well) were 
preincubated in 250 µl of FCS- and P/S-free RPMI medium, allowing complexation at 
RT for 10 min. To eliminate possible effects caused by the transfection reagent, 
some cells only received INTERFERinTM without siRNA (= IF control). The complex 
was provided in the 12-well plate and 125,000 cells, in P/S-free RPMI medium 
containing 10% FCS, were pipetted to each well. After cell adhesion to the bottom of 
the plate, medium was replaced the following day by fresh, P/S- and FCS-containing 
RPMI medium. Cells were maintained for 48 h or 72 h, at 37°C at 5% CO 2 until they 
were harvested for RNA and protein isolation. 
 
2.10  Isolation of primary murine hepatocytes 
 
For hepatocyte isolation, the collagenase perfusion method was used. Both sexes of 
p62 transgenic and control mice aged 7-8 weeks were examined.  
 
2.10.1  Collagenase perfusion 
 
All buffer solutions were prepared freshly and tempered to 37°C until use. 
Collagenase A is added to the collagenase buffer directly before perfusion. Stock 
solutions were kept at RT or at 4°C and were replac ed every 4 weeks (see 
supplement for detailed composition). As a peristaltic pump, maintaining the flow-
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through of the perfusion solutions, the Sci-Q 323 from Watson-Marlow (Roth, 
Karlsruhe, Germany) was used. 
 
Mice received an intra-peritoneal anaesthesia (Rompun 2%: Xylazinchloride 5-20 
mg/kg b. w. + Ketamin 10%: Ketaminchlorid 75-100 mg/kg b. w.). As soon as no 
body reflexes were recognisable, the top skin layer was desinfected with 70% 
isopropanol and opened. Another disinfection step was carried out before the 
abdominal wall was opened. The inner organs were carefully put aside to gain 
access to the Vena cava inferior. A canula was introduced into the Vena cava after 
the vein was truncated with a scissor. Perfusion started with EGTA-buffer and soon 
after the liver was swelling due to buffer accumulation, a load-relieve was set into the 
Vena cava right under the heart. Perfusion with ~50 ml EGTA-buffer persisted 5 min 
at 25 rpm. Subsequently, the buffer was exchanged to collagenase buffer. After 
approximately 6 min of perfusion, the liver tissue was removed and placed in a cell 
culture dish containing suspension buffer. The bovine serum albumine (BSA) in this 
buffer efficiently inhibits the activity of collagenase A and therefore stops further 
digestion of the liver. The liver capsule is carefully minced with two forceps for 
hepatocyte release. Cells were transferred into a Falcon tube and put on ice.  
 
The following experimental steps were done under sterile conditions under a laminar-
air flow.  
 
The hepatocyte cell suspension was carefully filtered through a cell strainer and 
transferred into a Falcon tube. Cells were washed with suspension buffer, followed 
by centrifugation for 5 min at 37 x g, before they were carefully resuspended in 10 ml 
suspension buffer. For determination of cell viability the suspension was diluted 1:5 
with suspension buffer. This dilution was mixed 1:1 with trypan blue and living as well 
as dead cells were counted in an improved Neubauer counting chamber. Cells were 
cultured on collagen-coated plates for adjacent experiments when cell viability was 
80% or more. Four hours after plating, when cells adhered to the collagen-coated 
bottom, medium was refreshed.  
 
For mRNA stability and caspase-3-like activity experiments, medium was replaced by 
FCS-free William´ s medium E (Gibco, Invitrogen, Karlsruhe, Germany) two hours 
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before the experiments started and cells were maintained under serum-free 
conditions until harvest.  
 
2.11  Caspase-3-like activity assay 
 
In normal cells, caspases exist as inactive proenzymes that undergo proteolytic 
cleavage arranged in cascades during apoptosis. The downstream effector caspase-
3 has been identified as being a key mediator of programmed cell death in 
mammalian cells (Hengartner 2000). It has been shown that caspase-3 cleaves 
PARP [poly- (ADP-ribose) polymerase], an enzyme that is involved in DNA repair 
and genomic maintenance. The upstream sequence of the PARP cleavage site, 
DEVD (N-acetyl-Asp-Glu-Val-Asp), is utilized as a basis for the highly specific 
caspase-3 substrate DEVD-AFC (7-amino-4-trifluoromethylcoumarin). Caspase-3 
cleaves the tetra-peptide after the aspartate residue, thus releasing the dye which 
can be quantified by UV spectrofluorometry (extinction wave length: 400 nm / 
emission wave length: 505 nm). This assay is termed ‘Caspase-3-like activity’ due to 
the fact, that other downstream caspases besides caspase-3 (e. g. caspase-7) show 
similar substrate specifity.  
 
2.11.1  Measurement of caspase-3-like activity in murine hepatocytes 
 
Apoptosis in hepatocytes (500,000 cells/well; 6-well cell culture plate) from p62 
transgenic and control mice was induced by addition of 0.4 µg/ml Actinomycin D (Act 
D) for 15 min at 37°C with 5% CO 2, followed by incubation with TNFα (100 ng/ml) for 
20 h in a humidified cell incubator. Medium was removed, cells were washed twice 
with 1x PBS, and 120 µl lysis buffer was added to each well. To complete cell lysis, 
cells were stored at -80°C o. n. Thawing was perfor med on ice. Cells were detached 
from the bottom of the plate with a cell scraper and transferred into Eppendorf tubes. 
After centrifugation at 13,000 x g at 4°C for 15 min, 10 µl of the supernatant was 
pipeted into a 96-well tissue culture plate. Subsequently 90 µl of the substrate buffer 
solution was added. Measurements of the generation of free AFC were performed in 
triplicates in a fluorometer multiplate reader (Wallac VICTOR2, Perkin Elmer, 
Rodgau-Jügesheim, Germany). Protein concentration of the corresponding samples 
was measured with the Bradford assay using a BSA standard.  
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2.11.2   Measurement of caspase-3-like activity in liver tissue 
 
Protein isolation from whole liver lysates, followed by the determination of the protein 
concentration was performed as described in 2.8.1. and 2.8.3. 10 µl of the protein 
lysate was pipeted into a 96-well tissue culture plate subsequently, 90 µl of the 
substrate buffer solution was added. Measurements were performed as described in 
2.11.1. 
 
2.12  Actinomycin D treatment and mRNA half-life estimation 
 
Transcriptional arrest followed by the measurement of mRNA levels of the transcripts 
of interest after certain time points, using real-time RT-PCR, allows the determination 
of the stability of the corresponding mRNA. To illuminate the question whether the 
reduction in the mRNA expression level results from reduced mRNA stability or from 
reduced transcriptional activity, transcription in murine hepatocytes was blocked by 
actinomycin D (Act D) for up to 10 hours.  
Act D blocks transcription through intercalation. By binding DNA during the 
elongation process, it prevents DNA-dependent RNA polymerase III from synthesis 
of the complementary mRNA strand. 
 
1.0 mg/ml Act D was dissolved in 100% ethanol (=stock solution), stored at -20°C for 
a maximum of 4 weeks, and diluted in cell culture medium to a final concentration of 
10 µg/ml.  
 
Experiments were performed the day after cell isolation. All cells were treated at 
different time points, but harvested simultaneously (0/4/6/8/10 hours) after Act D 
incubation. Therefore, the cell culture medium was removed, cells were washed 
twice with 1x PBS and 500 µl Qiazol lysis reagent was added to each well. Cells 
were detached from the plate bottom with a cell scraper and transferred into 
Eppendorf tubes. Until RNA isolation, samples were stored at -80°C. 
 Methods 59 
2.13  Histological staining 
 
All histological staining were performed in the Institute of Pathology, Saarland 
University, Homburg/Saar (Germany) with kind assistance from Prof. Dr. Rainer M. 
Bohle, MTA Gertrud Walter and MTA Sieglinde Wagner.  
 
2.13.1 Fixation and embedding of liver tissue 
 
2.13.1.1 Cryostat histology 
 
For preparation of cryostat sections, tissues have to be cut into small blocks of 
several mm length and shock frozen in liquid nitrogen. Fixation of the tissue block as 
done in paraffin histology is not necessary. Directly before cutting sections, the tissue 
block has to be placed on a holder, which is prepared with cryostat embedding liquid.  
 
In this set of experiments sections were cut at 8 µm. Sections were mounted on 
Superfrost slides (Menzel GmbH, Braunschweig, Germany) and air-dried. 
Cyrosections were used for lipid staining and counter-stained with haematoxylin-
eosin (HE). 
 
2.13.1.2  Paraffin histology 
 
Paraffin embedded tissues require a more complex reprocessing but result in a much 
better conservation of the tissue structure. Tissues were kept in 4% neutral buffered 
formaldehyde for fixation (24 h) immediately after organ removal. Formaldehyde is 
the most commonly used fixative for immunohistology. Fixed tissues have to be 
embedded before it is possible to cut sections. Routinely, this is done in paraffin. 
 
After formalin fixation dehydration is carried out with an increasing alcohol series 
consisting of isopropanol 80%, 90% and 100%, followed by incubation in an 
intermediate medium like xylol, before the tissue blocks are embedded in paraffin.  
 
Paraffin-embedding procedures were kindly performed at the Institute of Pathology. 
Paraffin blocks were stored at RT and protected from moisture. 
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2.13.1.3   Preparation of slides 
 
For slide preparation a microtome is used. Hereby, it is possible to cut slides of 2 µm 
size. It is necessary to cool paraffin blocks down to -20°C before usage. The 
obtained section has to be straightened in a water bath (tempered 40°C) before it is 
mounted on a slide. Before immunostaining, slides have to be dried o. n. at ~37°C.  
 
Sections from p62 transgenic mice were placed on the slide together with a section 
from a control mouse not expressing the transgene. 
 
2.13.1.4 Embedding of stained slides 
 
After staining is finished, slides have to be rinsed in water and dehydrated in a 
decreasing alcohol and xylol series before embedding for long-term storage in 
Entellan® (solution of synthetic resin-bound polymers in xylene) is performed. One to 
two drops of Entellan® are put on the slide and a coverslip is placed air-bubble free 
over the section. 
 
2.13.2   Routine staining 
 
To evaluate pathological changes in the architecture and physiology in tissues, 
several staining methods are used. Routinely, HE-staining is carried out. The cell 
nucleus is stained magenta-blue whereas the cytoplasm appears red-pink.  
 
2.13.2.1   Periodic acid Schiff staining (PAS) 
 
High proportions of carbohydrate macromolcules, e.g. glycoproteins, 
polysaccharides, glycolipids, phospholipids, and unsaturated fatty acids in the tissue 
can be visualised by PAS staining (Mulisch 1989). This method is primarily used to 
identify glycogen. The reaction of periodic acid selectively oxidizes the glucose 
residues, thereby creating aldehydes that react with the colourless acid fuchsine in 
Schiff reagent resulting in a purple-magenta color. Cell nuclei are counter-stained 
with haematoxyllin.  
 
 Methods 61 
As lipids are dissolved from the tissue by any alcohol treatment of the slide, PAS 
staining on paraffin sections can only detect lipids indirectly as cavities in the tissue 
structure.  
 
2 µm thick paraffin tissue sections were produced and staining was performed 
automatically in a staining machine.  
 
2.13.2.2 Scharlach Red staining 
 
The principle of this method lies on the better solubility of the dye in the tissue lipids 
than in the moderately apolar solvent, in which it is solubilised (Mulisch 1989). The 
lysochrome diazo-dye Sudan IV is allowed to permeate into the highly apolar fat 
without the solvent solubilising the fat to be stained. 
 
6-8 µm thick tissue sections were stained for 40 min in Scharlach Red and counter-
stained for 3 min in haematoxyllin. Embedding was done with a 1:1 solution of 
glycerol-HCl. 
 
2.13.2.3 Counter-staining 
 
Specific detection methods require counter-staining, e.g. immune detection results in 
a specific brown colour of certain tissue areas. To emphasise this staining and to be 
easily able to distinguish positively from negatively stained structures, a haematoxylin 
or haemalaun counter-staining follows, which particularly stains cell nuclei blue. 
 
2.13.3  Immunostaining 
 
With this method, it is possible to detect antigens in the tissue by using specific 
antibodies directed against the antigen of interest. A secondary antibody carrying a 
marker is directed against the primary antibody.  
 
The APAAP (alkaline phosphatase anti-alkaline phosphatase) method uses three 
antibodies. The primary binds to the antigen, the secondary is used as a “bridge” 
between the first and the third, binding to both. The third antibody is enzyme-marked 
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and directed against alkaline phosphatase. An advancement of this method is the so 
called DAKO REALTM EnVisionTM detection system method. Hereby, the secondary 
antibody is conjugated to a dextrane molecule carrying multiple horseradish-
peroxidase (HRP) residues.  
 
A second staining method applied in this work was ‘CSA II Biotin-free Tryamide 
Signal Amplification’ System (DAKO, Hamburg, Germany). The primary antibody is 
first detected with a peroxidase-conjugated secondary antibody. The next step 
utilizes the bound peroxides to catalyse oxidation of a fluorescein-conjugated phenol. 
Hereby, fluoresceyl-tryamide precipitates onto the specimen. The procedure is 
continued with the detection of bound fluorescein by a peroxidase-conjugated anti-
fluorescein. Staining is completed using DAB/hydrogen peroxide for visualization 
(source: DAKO CSA II kit manual).  
 
Both methods share the same visualisation technique. For detection, a transparent 
substrate diaminobenzidine (DAB) is applied on the slide. Through enzymatic 
reaction with peroxidase, a coloured precipitation is generated staining the tissue 
structures towards the primary antibody binds. For successful immune detection, it is 
necessary to perform several pre-treatments with paraffin-embedded tissue blocks.  
 
2.13.3.1  Heat-induced epitope retrieval (HIER) 
 
For the detection of several antigens, it can be necessary to treat samples with heat 
prior to staining. This is supposed to “renature” proteins, i.e. the sterical changes 
(e.g. protein cross-links) that proteins undergo during fixation, leading to epitope 
retrieval, are reversed. Slides were put in an open, heat-stable container containing 
citrate buffer, and incubated in a closed water bath for 20 min at 65°C. Slides are not 
allowed to run dry during the procedure. Afterwards, slides are cooled down to RT for 
30 min. 
 
Citrate buffer (pH 6.0) 
Tri-natrium-citrate-dihydrate (10 mM) 2.94 g 
Water ad     1.0 l 
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2.13.3.2  Peroxidase pre-treatment 
 
Endogenous peroxidases have to be blocked as they would cross-react with the DAB 
reagent, resulting in false positive staining. This procedure was carried out by 
application of DAKO REALTM peroxidase-blocking solution at RT for 15 min. During 
the incubation, it is important that slides are not covered.  
 
2.13.3.3  Biotin block 
 
If using the CSA II Signal Amplification System, it is necessary to block endogenous 
biotin in the tissue to eliminate potential background staining avoiding false positive 
signals. This procedure was carried out by application of serum-free protein block 
provided with the kit at RT for 5 min. The protein block was not rinsed off after 
treatment. 
 
2.13.3.4  CSA II kit staining procedure 
 
After the pre-treatment procedure, slides were incubated with the primary antibody 
for different incubation times. 
 
For usage with rabbit primary antibodies it is necessary to apply the CSA II rabbit link 
(DAKO, Hamburg, Germany) after incubation of the primary antibody, because the 
system is originally intended for the use with primary antibodies from mouse. The 
CSA II rabbit link was applied to cover the specimen and incubated for 30 min. In a 
next step, the amplification reagent was incubated for 15 min at RT. During this 
procedure, slides were protected against light. This step was followed by the 
application of Anti-Fluorescein-HRP labelled secondary antibody for 30 min. Finally, 
staining was performed by DAB substrate chromogen (CHROM) application onto the 
specimen for 5 min. Counterstaining was realized with HE for 30 sec and slides were 
mounted.  
 
During all incubation steps, slides were covered with coverslips and incubated in a 
humidified chamber to prevent them from drying out. Between all incubation steps, 
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the slides were carefully washed in 1x TBST. All steps in the procedure were carried 
out at RT. The kit was stored at 4°C and CHROM was prepared freshly every day. 
 
2.13.3.5  Detection using the DAKO REALTM EnVisonTM detection system 
 
In this work, also the DAKO REALTM EnVisonTM detection system with DAKO 
REALTM DAB+ (1-5% of 3,3´-diaminobenzidine hydrochloride) chromogene as 
visualisation reagent was applied. The dextran backbone is linked to up to 100 of 
peroxidase (HRP) molecules and up to 20 secondary antibody molecules coupled to 
it. The secondary antibody reacts with rabbit and mouse immunoglobulins.  
 
After the pre-treatment procedure, slides were incubated with the primary antibody 
for different incubation times at different temperatures (refer to supplement chapter 
7.5). After binding of the second, polymer-coupled antibody at RT for 30 min, the 
DAB-containing substrate working solution (CHROM) was mixed according to the 
manufacturer´ s instruction manual and applied to the slides for 8-10 min at RT. 
Haematoxylin counter-staining was performed for 2 min at RT. 
 
During all incubation steps, slides were covered with coverslips and incubated in a 
humidified chamber to prevent them from drying out. Between all incubation steps, 
the slides were carefully washed in 1x TBST. The kit was stored at 4°C and CHROM 
was prepared freshly every day. 
 
2.13.3.6  Quality control 
 
Unspecific binding can occur at different steps in the staining protocol, due to 
insufficient blocking of endogenous peroxidases, insufficient removal of paraffin or 
exhausted antigen retrieval. Usually, unspecific staining occurs because of 
undesirable binding of the primary antibody to unspecific structures in the tissue. 
Therefore, it is necessary to perform control experiments. 
 
Each staining run should include a negative control omitting the primary antibody to 
exclude non-specific staining, assuring at the same time the specificity of the primary 
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antibody. If non-specific staining is present, this will be recognized as a rather diffuse, 
brown staining on the slides.  
 
A positive control should ascertain a proper performance of all the applied reagents. 
Therefore, we stimulated mice with LPS for 15 and 30 min before tissue retrieval for 
the generation of positive control slides, supposing that the induction of the target 
antigen after LPS treatment was established (e.g. increase in NF-κB activation). 
Positive control slides should result in specific verification of the desired antigen.  
 
2.14   Intraperitoneal glucose tolerance test (IP-GTT) 
 
The blood glucose level is regulated by the hormones insuline and glucagone. 
Insuline lowers blood glucose levels by stimulating glucose uptake into the liver and 
muscle, at the same time blocking gluconeogenesis and lipolysis. On the contrary, 
the antagonist glucagon increases glycolysis leading to higher blood glucose levels. 
Determination and clinical outcome control of blood glucose levels are associated 
with hyperglycemias, like diabetes mellitus 
 
By performing intraperitoneal glucose tolerance tests (ip-GTT), it is possible to 
determine a time response of glucose decomposition in vivo. In this work, blood 
glucose was measured by the glucose dehydrogenase method using an Accu Check 
Aviva (Roche Diagnostics, Mannheim, Germany) glucometer. This method is based 
on the principle that glucose is converted into gluconolacton in the presence of a 
coenzyme (PQQ). During this reaction, released electrons build an electric current 
which is proportional to the glucose concentration in the sample. 
 
To minimize value variations, mice were fasted for 4 hours with free access to water. 
Mice were weighed and their tails were slit slightly with a scissor. By gently 
massaging the tail, a drop of blood was sampled onto a glucometer strip. The value 
from the baseline blood sample (0 min) was taken as the fasting glucose value. 
Afterwards, 10 µl/g body weight of a 20% glucose injection solution (Glucose-20% B. 
Braun, Melsungen, Germany) was administered intraperitoneally (i. p.). Subsequent 
blood samples were taken and glucose values were measured at 15 min, 30 min and 
75 min after injection. 
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2.15  Laboratory chemistry  
 
All serum parameters were determined by the ‘Zentrallabor des Universitätsklinikums 
des Saarlandes’ (Homburg, Germany) with kind assistance from MTA Marga Sand-
Hill and Prof. Dr. Jürgen Geisel.  
 
Mice were killed by cervical dislocation at the age of 2.5 weeks for blood sampling. 
To obtain the serum, whole blood was centrifuged for 10 min at 4,000 rpm before the 
supernatant was transferred into a fresh tube, diluted 1:3 with 0.9% NaCl, stored at   
-20°C and transported at 4°C until measurement. 
 
All samples were measured in a PPE Modular analyser using Roche® reagents at a 
constant temperature of 37°C (Roche Diagnostics, Ma nnheim, Germany). 
 
2.15.1   Enzymes 
 
Enzymes are biomolecules which catalyze chemical reactions (i. e. by lowering 
activation energy, they increase the conversion rate of substrates). Enzymes are 
solved in the cytoplasm or bound to specific cell compartments. Higher plasma 
enzyme levels are caused either by a physiological increase in enzyme synthesis 
during growth or by pathophysiological lesons in the cell membrane. Enzyme activity 
measurements are usually based on the principle of a photometrically determined 
change in absorption which is proportional to the enzyme activity. The measurement 
unit of 1 U corresponds to the turnover of 1 µmol substrate per minute. Determination 
of plasma enzyme concentrations is important in the diagnosis of tissue damage as 
well as for the severity and dimension of the damage. 
 
2.15.1.1  Transaminases 
 
Transaminases, i. e. alanine amino transferase ALT (GPT) and aspartate amino 
transferase AST (GOT) belong to a group of enzymes, which reversibly convert 
amino acids into the corresponding α-keto acids by transferring amino groups to 
coenzymes. Both transaminases were determined according to the International 
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Federation of Clinical Chemistry (IFCC). 7 µl of serum were measured. In case of the 
analyser making a second dilution of 1:20, 14 µl were used.  
 
2.15.1.1.1 ALT (GPT) 
 
ALT is located in the cytoplasm. Highest concentrations occur in the liver, followed by 
other organs like heart, kidney, skeletal muscle, pancreas, spleen and lung. ALT 
determinations are preliminary used for the diagnosis of liver parenchymal damage.  
 
Test principle: 
1. L-alanine + pyridoxalphosphate enzyme complex →  
  pyruvate + pyridoxaminphosphate enzyme complex 
 2. α- Ketoglutarat + pyridoxaminphosphate enzyme complex → 
  L-glutamate + pyridoxalphosphate enzyme complex 
 
The increase in pyruvate is measured in the linked lactate dehydrogenase reaction. 
 Pyruvate + NADH + H+ → lactate + NAD+ 
 
The speed of the decrease in extinction at a wave-length of 340 nm is determined by 
the degradation rate of NADH which is proportional to the development of pyruvate 
and therefore to the ALT activity. 
 
2.15.1.1.2 AST (GOT) 
 
70% of AST is bound to the mitochondria whereas 30% are located in the cytoplasm. 
With an increase in severity of the damage, the fraction of AST from the mitochondria 
will rise. A pathophysiological increase in AST levels is observed during liver, heart 
and skeletal muscle damages as well as in haemolysis. 
 
Test principle: 
1. L-aspartate + pyridoxalphosphate enzyme complex →    
  oxalacetate + pyridoxaminphosphate enzyme complex 
2. α- Ketoglutarat + pyridoxaminphosphate enzyme complex → 
  L-glutamate + pyridoxalphosphate enzyme complex 
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The increase in oxalic acetate is determined in the linked malate dehydrogenase 
reaction. 
Oxalic acetate + NADH + H+ → malate + NAD+ 
 
The speed of the decrease in extinction at a wave-length of 340 nm is determined by 
the degradation rate of NADH which is proportional to the development of oxalic 
acetate and therefore to the AST activity. 
 
2.15.2   Substrates and metabolites 
 
Substrates participate in metabolism. Physiological concentrations are normally kept 
up in the plasma. Often, the level of organ specific substrates does not change until 
metabolism and organ function are severely disturbed. 
 
2.15.2.1 Cholesterol and HDL 
 
Cholesterol is a lipidic steroid primarily synthesized de novo in the liver, required for 
membrane permeability and fluidity. Plasma cholesterol is bound to lipoproteins, 
which can be fractionized into low density lipoprotein (LDL), high density lipoprotein 
(HDL); very low density lipoprotein (VDL), and chylomicrons. HDL particles are 
thought to transport cholesterol back to the liver for excretion or to other tissues that 
use cholesterol to synthesize hormones.  
 
High levels of cholesterol in the blood are strongly associated with atherosclerosis 
and with lipid metabolic disorders. Hypercholesterolemia is diagnosed with several 
diseases, among which are cholestasis, cirrhosis and diabetes mellitus, while high 
levels of HDL correlate with a better health outcome. 
 
2.15.2.2   Triglycerides 
 
Triacylglycerol is a glyceride in which glycerol is esterified with three fatty acids. High 
levels of triglycerides are linked to atherosclerosis, heart disease and stroke and 
pancreatitis. Triglyceride measurements are used for the diagnosis of lipid metabolic 
disorders and for the classification of hyperlipidemias.  
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Cholesterol and triglycerides were measured according to the CHOD-PAP method. 
Detergents release cholesterol and his esters from lipoproteins. Cholesterol esterase 
hydrolyzes cholesterol which is then oxidized by cholesteroloxidase. Thereby, 
hydrogen peroxide is built, which is in the presence of peroxidase and 4-
aminoantipyrine, converted into chinonimine. Triglycerides were hydrolysed to 
glycerol and fatty acids. Glycerol is oxidized and thereby hydrogen peroxide is built.  
 
The resulting dye is measured at a wave-length of 505 nm. The intensity of the colour 
is thereby proportional to the concentration of triglycerides. HDL was determined by a 
homogenic enzymatic test. For measurement of cholesterol and triglycerides 2 µl 
serum and for measurement of HDL 2.1 µl of serum were used. 
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3.  Results 
 
p62 was originally identified as tumor-associated autoantigen in HCC (Zhang, Chan 
et al. 1999) but biological actions of the protein have as yet been completely 
unknown.  
 
Therefore, mice overexpressing p62 exclusively in the liver were generated by the 
group of Dr. Tan (The Scripps Research Institute, La Jolla, USA) in order to 
investigate functional implications of hepatic p62 expression. 
 
3.1  Liver specific expression of p62  
 
The chromosomal insertion of the transgene for the mouse lineage used for all 
experimental procedures is not known.  
 
Northern and Western Blots revealed that neither p62+/LT2- nor p62-/LT2+ mice but 
solely double-positive p62+/LT2+ mice from both lineages express p62 in the liver 
(Figure 15, data kindly provided by Dr. Fu-Dong Shi and data not shown). 
 
Doxycyclin administration abrogated p62 expression (data not shown, experiments 
performed by PD Dr.Alexandra K. Kiemer). 
 
All single- and double-transgenic mice are fertile and show normal development. No 
spontanous occurence of liver tumours for up to two years was observed. 
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Figure 15:  Northern Blot. 
p62 expression in different mouse organs. Only in livers of p62 
transgenic mice the 2.0 kb band corresponding to p62 mRNA could 
be detected. 
 
 
All experiments were performed either in liver tissue or in isolated hepatocytes from 
p62 transgenic mice (+/+: “p62”) in comparison to control mice (-/+: “co”) carrying the 
liver specific promoter but showing no overexpression of the p62 transgene. Mice 
homo- and heterozygous of both groups were used for the experiments.  
 
Figure 16 shows that p62 expression is restricted to the cytoplasm and that the 
transgene is expressed in a high percentage of hepatocytes.  
          co                       p62 
 
Figure 16: p62 localization.  
Immunostaining of p62 in liver tissue. An increase in cytoplasmic 
staining was detected in p62 transgenic animals (right, p62) in 
comparison to controls (left, co) (paraffin-embedded; 20x original 
magnification). 
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3.1.1   Genotyping of p62 mice 
 
For genotyping of mice, a PCR was performed with two primer pairs, which allows 
detection of the p62 transgene and the LT2 gene. With the primer pair “p62 lower” 
and “p62 upper” a band of 350 bp was detected, whereas the primer pair “LT2 lower” 
and “LT2 upper” detected a band of 500 bp in size. With the PCR reaction, all 
possible genotypes can be detected. Figure 17 illustrates the two possible 
amplification products.  
 
In p62-/LT2+ mice only one band of 500 bp appeared, corresponding to the LT2 gene, 
whereas in p62+/LT2+ mice, two bands could be detected, one of 500 bp and one of 
350 bp, the latter corresponding to the p62 transgene. Also p62+/LT2- mice were 
detected, corresponding to a 350 bp band in size in the absence of a 500 bp LT2 
band (data not shown). These mice do not overexpress the transgene. 
 
 
 
Figure 17:  Genotyping of p62 transgenic mice.  
PCR products were loaded onto a 1.5% agarose gel. The 500 bp 
band corresponds to LT2, the 350 bp band matches p62.  
 
 
3.1.2   Genotyping of p62/LT2/SD7 mice by allele-specific PCR 
 
For the imprinting analyses, mice were selected for the insertion of the Mus spretus 
into the Mus domesticus background. SD7 mice carry the Mus spretus distal 
chromosome 7 on a C57BL/6 Mus domesticus background. By crossing these mice 
with mice on a Mus domesticus background, the inheritance of the parental alleles 
can be examined. To distinguish between the Mus spretus and the Mus domesticus 
background, two PCR reactions using microsatellite primers were performed to 
analyse the recombination events in the progeny of p62 x SD7 mice.  
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Microsatellites (also called single sequence repeats, SSR) are sequences composed 
of tandem repeats from one to six bases in length, which are arranged head-to-tail 
without interruption (Hancock, Worthey et al. 2001). 
  
The primer pair “D7 Mit 12 for” and “D7 Mit 12 rev” detected a band of 220 bp 
corresponding to the Mus spretus background, whereas a band of 197 bp was 
detected on the Mus domesticus C57BL/6 background (Figure 18 A). Only mice 
where both bands were detected in the genotyping PCR were selected for the 
experiments. 
 
The primer pair “D7 Mit 140 for” and “D7 Mit 140 rev” detected a band of 125 bp 
corresponding to the Mus spretus background. The band of 137 bp appeared when a 
Mus domesticus background existed (Figure 18 B). Only mice showing both bands in 
the genotyping PCR were used for the experiments. 
 
 
 
A 
 
 
 
 
B 
 
    
 
 
Figure 18: Genotyping of the progeny of p62 x SD7. 
A Bands show PCR products from “D7 Mit 12” amplification. The band 
of 220 bp in size corresponds to the Mus spretus origin of the parental 
allele. The band of 197 bp in size relates to the Mus domesticus 
origin. 
B Bands show PCR products from “D7 Mit 140” amplification The band 
of 125 bp corresponds to the Mus spretus origin, whereas the band of 
137 bp relates to the Mus domesticus origin. 
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3.1.3  p62 expression 
 
Figure 19 show that 5 week old p62 transgenic animals displayed the highest levels 
of p62 mRNA. 
 
 
 
Figure 19:  p62 mRNA expression.  
p62 expression was determined by real-time RT-PCR in p62 
transgenic mice (n>6), expressed as the mean ± S.E.M. A value of 
p<0.005 (*) represented a statistically significant difference compared 
to controls using student´ s t-test. 
 
 
3.2  Induction of a fatty liver disease phenotype 
 
In order to investigate changes in liver morphology caused by p62 overexpression, 
histological investigations were performed on liver tissue from p62 transgenic and 
control mice. Mice at the age of 2.5 and 5 weeks were examined.  
 
3.2.1   HE  
 
HE staining of sections suggested morphological changes in p62 transgenic livers. 
Stainings showed a homogenous distribution of HE in healthy tissue, whereas in p62 
transgenic livers the cytoplasm of eosinophilic cells, predominately located around 
the central veins (Rappaport zone 1), were stained stronger than pericentral and 
central-lobular (Rappaport zones 2 + 3)  (Rappaport 1960; Rappaport 1976) 
cytoplasmic areas, where basophilic cells predominated (Figure 20).  
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Leukocyte infiltration was not observed with p62 overexpression. Examination of 
livers from 5 week old animals displayed no such staining differences. Leukocyte 
infiltration was not elevated under p62 overexpression in both groups. 
 
    co          p62   
 
 
Figure 20:  Histological alterations in 2.5 week old mice.  
HE-stained liver tissue of control mice (left, co) in comparison to p62  
transgenic animals (right, p62) (paraffin-embedded, 20x original 
magnification). Basophilic cells are shown in both groups, whereas 
eosinophilic cells were only detected in p62 transgenic animals. Areas 
of basophilic cells (→) are pericentrally located. (►)displays 
accumulation of eosinophilic cells. 
 
 
3.2.2  Scharlach Red  
 
Liver architecture gave hints on an accumulation of fatty acids as presumed from the 
occurrence of empty vacuoles in paraffin-embedded liver tissue. Therefore, 
investigations on specific fat staining were performed. In comparison to controls, the 
p62 transgenic tissue of 2.5 week old mice showed a significant increase in finely 
dispersed fat droplets without a zonal preference (Figure 21).  
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Figure 21:  Fat droplets in 2.5 week old mice. 
Scharlach Red stained cryosected liver tissues of controls (left, co) in 
comparison to p62 transgenic mice (right, p62) (cryosected; 40x 
original magnification). A microvesicular distribution of fatty acids 
occurred in hepatocytes of transgenic animals. 
 
In 2.5 week old animals, 21 transgenic livers were stained and compared to 14 
controls. 12 transgenic livers, i. e. 57% showed a strong reaction with Scharlach Red 
due to the accumulation of fat, revealing the phenotype of a fatty liver. 
 
p62 transgenic females displayed a higher frequency in the occurrence of the fatty 
liver phenotype (66%) when compared to males (44%). In addition to microscopic 
differences, fatty livers macroscopically occurred with pale colour (data not shown). 
 
For the age of 5 weeks, no significant difference was observed between the two 
experimental groups (data not shown). 
 
3.2.3   PAS 
 
Metabolic differences were also seen regarding carbohydrate macromolecules, i. e. 
glycogen. At the age of 2.5 weeks, a decrease in glycogen staining was observed in 
livers of p62 transgenic mice (n=12) in comparison to controls (n=7) (Figure 22). 
Whereas an accumulation of glycogen in Rappaport zones 1 + 2 around the central 
veins could be detected in some transgenics (n=4), others displayed a homogenic 
distribution with no zonal preference (n=8).  
 Results 77 
For 5 week old mice, no significant changes between the two groups could be found 
(data not shown).  
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Figure 22:  Glycogen staining. 
PAS-stained liver tissue of control animals (left, co) in comparison to 
p62 transgenic animals (right, p62) (paraffin-embedded; 20x original 
magnification). (→) show the accumulation of glycogen around the 
central vein in p62 transgenic animals. 
 
3.3  Increased liver to body weight ratio 
 
Fatty livers might result from higher body weight due to impaired hepatic lipid export 
and favoured hepatic triglyceride (TG) accumulation (Angulo 2002). As we could 
detect hints on pathological changes similar to steatosis and steatohepatitis occurring 
under p62 overexpression, we were interested in potential changes in liver and/or 
body weight. 
 
For neither body nor liver weight, we could detect any significant differences between 
both examined groups at the age of 2.5, 5 and 10 weeks. Moreover, no gender-
specific differences were detected (data not shown). 
 
Interestingly, at the age of 2.5 weeks when the phenotypic alterations caused by p62 
overexpression were highest, the liver to body weight ratio revealed a significant 
difference between control and transgenic mice (Figure 23).  
 
→ 
→ 
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Figure 23:  Liver to body weight ratio. 
Liver to body weight ratio of 2.5 (co: n=26 / tr: n=29), 5 (co: n=12 / tr: 
n=12) and 10 (co: n=6/ tr: n=3) week old mice, expressed as the 
ratio*1000, representing the mean ± S.E.M. A p<0.05 (*) represents a 
statistically significant difference compared to controls using student´s 
t-test. 
 
 
3.4   Absence of liver damage 
 
Since alterations in metabolism and liver architecture were revealed only in 2.5 week 
old mice, we decided to determine lipid (cholesterol, HDLC, triglycerides) serum 
parameters also in this age group. Since the incidence of fatty livers seemed higher 
in female animals, we also considered gender-specific differences.  
 
3.4.1  Serum lipids 
 
No relevant differences in cholesterol or HDLC values were revealed, neither with 
regard to gender-specificity nor to the experimental groups (Table 1). 
 
Interestingly, a significant increase in triglyceride serum levels was found when p62 
transgenic male mice were compared to their corresponding control littermates 
(Table 1), whereas no difference was detected for females. 
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         HDLC           CHOL            TG 
both 
sexes 
         87 ± 5           102 ± 6        104 ± 12 
male         102 ± 7           108 ± 7          73 ± 7  
                 
      co             
                 
female          84 ± 5             93 ± 5        144 ± 15 
both 
sexes 
         84 ± 6           103 ± 7        104 ± 13 
male          90 ± 9             90 ±11        109 ± 8 
      (*p<0.05) 
                 
     p62           
                 
female          86 ± 6            105 ± 5        125 ± 37 
 
Table 1: Serum parameters of 2.5 week old p62 transgenic mice. 
Determination of lipid serum parameters in p62 transgenic mice 
(n=10, of which n=6 male and n=4 female) after 4 hours of fasting vs. 
controls (n=16, of which n=9 male and n= 7 female). Serum 
parameters expressed in mg/dl, representing the mean ± S.E.M. A 
value of p<0.05 (*) was considered statistically significant from 
respective controls using student´ s t-test. 
 
 
3.5    Absence of inflammatory parameters 
 
Since p62 transgenic animals developed histological liver alterations similar to a non-
alcoholic fatty liver disease (NAFLD), we aimed to determine whether they also show 
characteristics of a non-alcoholic steatohepatitis (NASH), additionally encompassing 
inflammation.  
 
3.5.1  Serum transaminases 
 
Since alterations in liver architecture occured in 2.5 week old mice only, serum 
transaminase (ALT, AST) parameters were examined only in this age group. Due to 
the preferred incidence of fatty livers in female animals, gender-specific differences 
were also considered. 
 
ALT levels displayed a decrease in transgenic mice compared to controls, with a 
difference being most considerable in female animals.  
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Determination of serum AST levels, which would also indicate liver damage, showed 
the same non-significant result, with the most potent decrease in female 
transgenics´. 
The de Ritis ratio showed a significant increase in p62 transgenic females (Table 2). 
Although this single result might be interpreted as a hint on perturbations in liver 
function, the data do not suggest that a pronounced liver damage is induced in p62 
transgenic animals. 
 
 
ALT AST De Ritis 
ratio 
both sexes 357 ± 40 2564 ± 299 6.29 ± 0.25 
male 312 ± 36 2289 ± 189 7.65 ± 0.55 
            
co        
            female 439 ± 112 2488 ± 592 4.02 ± 0.76 
both sexes 263 ± 43 1749 ± 254 5.99 ± 0.32 
male 278 ± 56 1972 ± 437 5.45 ± 1.35             p62      
            female 248 ± 27 1677 ± 840 6.81 ± 0.88   (*p<0.05) 
  
Table 2:  Transaminase levels. 
Serum ALT and AST levels (U/l) determined after 4 hours of fasting of 
p62 transgenic mice (n=7, of which n=4 male and n=3 female) vs. 
controls (n=14, of which n=9 male and n=5 female). Data are 
expressed as the mean ± S.E.M. A value of p<0.05 (*) was 
considered statistically significant from controls of the respective 
gender using student´ s t-test. 
 
 
3.5.2  Immunohistology of NF-кB 
 
Although the absence of leukocyte infiltration did not suggest any signs of 
inflammation, a potential activation/ translocation of NF-кB (p65 subunit) was 
investigated, which plays a pivotal role in the inflammatory response (Winwood and 
Arthur 1993; Luedde, Beraza et al. 2006).  
 
15 min and 30 min LPS stimulated livers from C57BL/6 mice served as positive 
controls. Staining in LPS-treated positive control livers displayed an increase in 
nuclear staining of immune cells but neither in cytoplasmic nor nuclear staining of 
hepatocytes (Figure 24 A).  
 
p62 transgenic livers did not show increased nuclear p65 staining, indicating 
inflammatory activity (Figure 24 B). Therefore, it can be concluded that p62 does not 
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promote chronic inflammatory processes as already indicated by serum parameter 
values and by the absence of observed leukocyte infiltration.  
Interestingly, an increase in cytoplasmic staining of hepatocytes in p62 transgenic 
mice was revealed in 12 of 15 animals (80%). Moreover, about one third of the 
transgenic livers displayed a higher occurrence of positively stained hepatocytes in 
Rappaport zone 3.  
For 5 week old mice, no difference in neither cytoplasmic nor nuclear staining of liver 
cells between both experimental groups could be revealed (data not shown). 
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             B 
 
 
   
 
 
 
 
 
 
 
Figure 24: 20x original magnification of paraffin-embedded slides.  
Immunostaining of NF-кB p65. 
A NF-кB (p65) stained liver tissues 15 min (left) and 30 min (right) after 
LPS treatment. The increase in nuclear staining of immune cells is 
indicated by arrows (►). 
B NF-кB (p65) stained liver tissue of p62 mice (left: co), (right: p62). An 
increase in cytoplasmic hepatocyte staining was detected for p62 
transgenic animals. 
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3.6   Increased expression of IGF2 and H19  
 
Since p62 belongs to the family of IGF2 mRNA-binding proteins (Zhang, Chan et al. 
1999) and due to the fact that IGF2 has been associated with metabolic disorders, 
we were interested in potential changes in IGF2 expression in p62 transgenic mice. 
At the same time H19 was determined, due to the fact of the similar regulation of 
both genes by genomic imprinting (Sasaki, Ishihara et al. 2000). 
 
For all investigated ages (2.5, 5 and 10 weeks) an upregulation of IGF2 and H19 
could be shown for p62 transgenic animals in comparison to controls (Figure 25).  
 
Interstingly, however, expression of both IGF2 and H19 was highest at the age of 2.5 
weeks when phenotypic alterations were most obvious. 
 
At the age of 2.5 and 5 weeks a significant upregulation of IGF2 and H19 could be 
shown for p62 transgenic mice in comparison to control animals. 10 week old 
animals followed that tendency. 
 
 
 
Figure 25:  Time course of mRNA expression. 
Log ratio of IGF2 and H19 to 18S in p62 transgenic mice vs. controls, 
expressed as the mean ± S.E.M. Experiments were performed for a 
minimum of n=6 mice per group. A value of p<0.05 (*), a p<0.005 (**) 
and a p<0.001 (***) was considered statistically different from controls 
at the respective age using student´ s t-test. 
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Correlation data revealed that with raised p62 expression, the induction of IGF2 and 
H19 increased within one age group (Figure 26). Increased IGF2 expresssion was 
accompanied by elevated H19 expression. Noteworthy, female p62 transgenic mice 
displayed higher levels of p62, IGF2 and H19 than their corresponding male 
littermates.  
 
 
 
Figure 26:  Correlation graphics of p62, IGF2 and H19 mRNA expression of 2.5 
week old p62 transgenic animals.  
p62 is expressed as the ratio normalized to 18S and blotted against 
the x-fold values of IGF2 (B) or H19 (C) compared to controls. 
Correlation between IGF2 and H19 mRNA expression (D), expressed 
as x-fold values of control (n=4) and transgenic (n=9) mice. ♀ shows 
gene expression levels in female p62 transgenic animals. 
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To exclude genetic predisposition, the correlation of p62, IGF2 and H19 gene 
expression was demonstrated after application of doxycycline to p62 transgenic 
mice.  
 
Doxycycline abrogated p62 expression, and a reduction in mRNA expression of IGF2 
and H19 could be verified by real-time RT-PCR (Figure 27, data kindly provided by 
Prof. Dr. A. K. Kiemer). 
 
 
 
Figure 27: Time course of mRNA expression after doxycycline (dox) 
administration.  
Ratio of p62, IGF2 and H19 normalized to 18S in p62 transgenic mice 
(dox) vs. untreated p62 transgenic animals (no dox), expressed as the 
mean ± S.E.M. 
 
 
3.7   Localisation of p62 and IGF2 
 
Staining of p62 and IGF2 in p62 transgenic livers revealed a diffuse pattern with 
areas of only weak staining and clusters of hepatocytes showing strong 
immunoreactivity within the cytoplasm and therefore high expression of p62 and 
IGF2. Both proteins are located in the cytoplasm. No zonal preference was observed 
(Figure 28). 
 
It is worth mentioning that immunostaining of p62 and IGF2 in serial sections from 
p62 transgenic livers demonstrated that hepatocytes, which display high expression 
levels of p62 showed an increase in IGF2 protein, too (Figure 28).  
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Figure 28:  Immunostaining of p62 and IGF2. 
Serial sections of the tissue of a 2.5 week old p62 transgenic liver, 
stained with an antibody against p62 (left) and IGF2 (right) (paraffin-
embedded; 20x magnification). Cells displaying strong immunostaing 
of p62 also showed increased IGF2 expression, indicated by (→). 
 
 
3.8   No alteration of IGF2 and H19 mRNA stability  
 
p62 is known to belong to the family of insulin-like growth-factor 2 mRNA-binding 
proteins (Nielsen, Christiansen et al. 1999). mRNA-binding proteins can play a role in 
the regulation of mRNA stability.  
 
Because of the fact that p62 expression resulted in an upregulation of IGF2 and H19 
mRNA levels and IMPs have been shown to bind also to H19 (Runge, Nielsen et al. 
2000), mRNA stability of IGF2 and H19 in p62 transgenic mice were estimated in 
isolated and actinomycin D (Act D) treated hepatocytes.  
 
Figure 15 shows that steady-state levels of all mRNAs decreased after treatment with 
Act D, but more than 60% of mRNA levels were left after 10 h suggesting high mRNA 
half-lives for all three transcripts (Eberhardt, Doller et al. 2007). The decay of IGF2 
and H19 was comparable between both experimental groups over the time course. 
These results indicate that both IGF2 and H19 stability is not altered by the presence 
of p62 (Figure 29). 
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Figure 29: mRNA stability. 
mRNA expression in hepatocytes isolated from p62 transgenic (n=3) 
vs. control (n=3) mice. Data are expressed as the mean ± S.E.M. 
relative mRNA expression after Act D (10 µg/ml) treatment for 4, 6, 8 
and 10 hours normalized to cyclophilin. Data expressed relative to 
untreated cells of the same isolation (0 h), set as 100%. 
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3.9   Monoallelic expression of IGF2 and H19 
 
To elucidate allele-specific expression of IGF2 and H19, single-nucleotide primer 
extension (SNuPE)-HPLC analysis was performed on liver tissues from newborns 
and 2.5 week old mice.  
 
To be able to distinguish between the origin of the paternal allele, SD7 mice (carrying 
the Mus spretus distal chromosome 7 on a C57BL/6 Mus domesticus background) 
were crossed with p62 transgenic mice (Moore, Constancia et al. 1997). SD7 mice 
provide a source of single-nucleotide polymorphisms (SNPs) to distinguish 
expression of all the genes present on this gene locus, including IGF2 and H19. 
 
For verification that endogenous, i. e. mup62, has no influence on allele-specific 
IGF2 or H19 expression, expression levels of mup62 were examined by real-time 
RT-PCR (Figure 30). Results showed a non-significant decrease in mup62 
expression in transgenic mice, which may be evoked by p62 overexpression. 
 
Real-time RT-PCR experiments on the cDNA of livers derived from p62 transgenic 
newborns showed only a weak increase in IGF2 and H19 compared to control 
animals (Figure 31). Since phenotypic alterations were most obvious when IGF2 and 
H19 expression was highest, a second set of experiments with 2.5 week old mice 
was performed. 
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Figure 30: mRNA expression of mup62 in newborn p62/SD7 mice.  
Data is expressed as the the relative expression ± S.E.M. Results 
show 1 experiment, performed with a minimum of 4 animals per 
group. 
 
 
            
Figure 31: IGF2 and H19 mRNA expression in newborn and 2.5 week p62/SD7 
mice.  
Data expressed as the x-fold values ± S.E.M. of transgenic vs. control 
animals. (*) p<0.05 statistically different from controls of the 
respective age using student´ s t-test. 
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Besides, cDNA was used for the amplification of IGF2 and H19 transcripts in SNuPE 
reactions. A 16 bp primer, which ends directly before the 3´ end of the polymorphism, 
is annealed and elongated by exactly one allele-specific didesoxynucleotide 
(ddNTP). The reaction is aborted after incorporation of a ddNTP because ddNTPs do 
not carry a free hydroxyl group at the 3´ residue and cannot be elongated.  
 
An aliquot of the SNuPE reaction was loaded onto an HPLC column and eluted DNA 
was detected with a UV detector at 260 nm.  
 
IGF2 products derived from the Mus domesticus background (p62) led to the addition 
of a ddTTP whereas IGF2 products derived from the Mus spretus background (SD7) 
resulted in a ddCTP. 
 
H19 products reciprocally correlated with the IGF2 results: the ddCTP concluded for 
the Mus domesticus background whereas a ddTTP originated from Mus spretus.  
 
After amplification three products can be distinguished from each other: 
 
unextended primer    5´ TCAGTGAATCAAATTA 3´ 
 
T-extended primer (M. dom.) 5´ TCAGTGAATCAAATTAddTTP 3´ 
     → reaction stopp 
 
C-extended primer (M.spret.) 5´ TCAGTGAATCAAATTAddCTP 3´ 
     → reaction stopp 
 
The three products can be distinguished according to their hydrophobicities, thereby 
following the principle that with increasing hydrophoby, eluation occurs earlier, i. e. 
the unextended primer lacking a base compared to the extended ones leaves the 
column first. As cytosine (C) is more hydrophilic than thymidine (T), products carrying 
a C are eluted earlier than products carrying a T. 
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For both examined ages, a mono-allelic expression of IGF2 and H19 was shown 
(Figure 32) in control as well as p62 transgenic mice: IGF2 is paternally and H19 is 
maternally expressed, as can be seen for values on the allele-specific index (Table 
3). 
 
  H19 MW H19 ± SEM IGF2 MW IGF2 ± SEM 
newborn transgenic mice 0.94 0.01 1.00 0.00 
newborn control mice 0.92 0.02 1.00 0.00 
2.5 week transgenic mice 1.00 0.00 1.00 0.00 
2.5 week control mice 1.00 0.00 1.00 0.00 
 
Table 3:  Allele-specific index of H19 and IGF2 expression after SnuPE-HPLC 
detection.  
Results are obtained by determination of the peak heights of the C- 
and T-extended primers and calculating the ratio h(C)/ h(C)+ h(T) 
(newborn: p62: n=7, co: n=6; 2.5 week: p62: n=8; co: n=4). No 
statistically significant difference could be determined between both 
examined groups. 
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Figure 32:  Allele-specific expression of IGF2 and H19.  
Representative HPLC chromatograms showing amplification products 
for IGF2 (above) and H19 (below) in the SNuPE reaction in 2.5 week 
old transgenic heterozygous p62/SD7 mice (n=8, right) vs. controls 
(n=4, left). 
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3.10   Correlation between p62 and IGF2 and H19 
in human hepatoma cells 
 
The relationship between p62 and IGF2/H19 observed in p62 transgenic mice was 
investigated also in human cells by knocking down p62 by siRNA and determine 
IGF2 and H19 expression. 
 
We decided to use different hepatoma cell lines due to variations in basal expression 
levels of p62. In contrast to Alexander cells, HepG2 and HUH7 express more p62 
protein (Figure 33). 
 
Figure 33:  p62 protein expression in three different human hepatoma cell lines. 
Protein expression was determined by Western Blot with 3.5 µg whole 
protein lysate loaded onto an 8% SDS gel.  
 
 
For each experiment, cells were treated with a random siRNA to exclude unspecific 
gene knockdown. Western Blot experiments underline the specificity of the p62 
siRNA. As Figure 34 points out, random siRNA did not lead to alterations in the 
protein expression of p62.  
 
The effect of siRNA-mediated knockdown of p62 was observed on the protein level 
after 48 h and 72 h (Figure 34), whereas no effect was observed 24 h after cell 
transfection (data not shown).  
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Figure 34:  p62 protein in human hepatoma cells after RNAi transfection.  
The 62kDa band of p62 was determined by Western Blot. The 
difference in protein expression is shown after 48 h and 72 h after 
siRNA-mediated gene knockdown of p62 (lane #3) in comparison to 
InterferinTM (lane #2) and random siRNA (lane #1) treated cells. Equal 
concentrations of 5 µg whole protein lysates were loaded per lane.  
 
 
The observations made on the protein level could be confirmed for mRNA.  
 
According to mRNA expression levels no significant difference for each examined 
cell line, time point and gene was measured for random siRNA and InterferinTM 
treatment (Figure 35), whereas a significant decrease of p62 mRNA was detected, 
coexistent with a significantly reduced mRNA expression of IGF2 and H19 (Figure 
35) after p62-siRNA-mediated gene-knockdown.  
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Figure 35:  mRNA expression in (A) HepG2 (upper left), (B) HUH7 (upper right) and (C) 
  Alexander cells (below) after siRNA-mediated knockdown of p62.  
mRNA expression of p62, IGF2 and H19 48 h (upper) and 72 h (lower). Gene 
expression is shown in % relative to controls (Interferin/mock treatment), 
representing the mean ± S.E.M. A value of p<0.05 (*), of p<0.005 (**) and of 
p<0.0005 (***) was considered statistically different using student´ s t-test, whereas 
no statistical significance was detected for random siRNA-treated cells. 
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In summary, the RNAi experiments confirmed the relation of IGF2, H19 and p62 in 
human hepatoma cells.  
 
Further experiments focussed on the question whether the influence of p62 on IGF2 
exerted functional consequences on protein kinase B/AKT and the inversely 
correlated PTEN pathway in p62 transgenic mice.  
 
3.11   Increased phosphorylation of the protein kinase AKT  
 
IGF2 dependent downstream signalling is known to exert anti-apoptotic effects via 
AKT to counteract programmed cell death while at the same time supporting cell 
proliferation (Cory, Vaux et al. 1999). 
AKT phosphorylation at Ser473 was examined in liver protein extracts from 2.5, 5 
and 10 week old mice. Significantly enhanced AKT phosphorylation was observed in 
transgenic livers from 5 and 10 week old animals, whereas 2.5 week old animals 
showed no changes (Figures 36 A + B). 
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Figure 36:  AKT activation. 
A Western Blot experiments showing the phosphorylation of AKT in 
transgenic p62 animals at the age of 2.5, 5 and 10 weeks normalized to α-
tubulin. 
B Quantification of (A) expressed as the mean x-fold values ± S.E.M. 
Values of (*) p<0.05 and (**) p<0.01 were considered statistically different 
compared to values of control animals of the respective age using student´ s t-
test. (2.5 weeks co: n=6, tr: n=7; 5 weeks co: n=4, tr: n=5; 10 weeks co: n= 7, 
tr: n=6). 
 
 
3.12   ActD/TNF-α-induced apoptosis protection 
 
The observation of activated AKT in p62 transgenic animals suggested a potential 
anti-apoptotic phenotype since pAKT can prevent cells from undergoing apoptosis. 
This is why the extent of apoptosis induction was assayed using hepatocytes derived 
from control as well as from p62 transgenic mice.  
 
Figure 37 A shows that hepatocytes from p62 transgenic mice displayed significantly 
lower caspase-3-like activity upon apoptosis induction by Act D/TNF-α when 
compared to control hepatocytes.  
 
In order to investigate whether programmed cell death was detected in p62 
transgenic livers in vivo, caspase activities in whole liver lysates were examined. 
However, p62 transgenic animals showed no significant differences to controls 
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(Figure 37 B). These results suggested a prominent apoptosis protection of 
hepatocytes in the presence of the p62 transgene. 
 
 
 A 
 
 
 
 B 
 
 
 
Figure 37:  
A Caspase-3-like activity in isolated hepatocytes. 
Hepatocytes were left untreated (co) or were treated with ActD for 15 
min followed by TNF-α-incubation for 20 h (ActD + TNF-α). Data are 
expressed as x-fold enzyme activity with control cells set as 1 
expressed as the mean ± S.E.M. (performed in triplicate). White 
columns show control mice (n=3), black columns show p62 transgenic 
mice (n=2). A value of p<0.001 (***) was considered statistically 
different from treated ActD/TNF-α non-transgenic hepatocytes. 
B Caspase-3-activity in liver tissue. 
Caspase-3-like activity in livers of 2.5, 5 and 10 week old p62 
transgenic animals is expressed in comparison to controls of the 
respective age set equal to 100%. The white column shows control 
mice (n=3 per age), black columns show p62 transgenic mice (n=3 
per age), expressed as the mean ± S.E.M. (performed in triplicate). 
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3.13   Decreased PTEN expression 
 
3.13.1  PTEN in p62 transgenic mice 
 
IGF2 is known to influence PTEN expression, which inversely correlates with the 
phosphorylation of AKT. As the Western Blot experiments revealed an increase in 
pAKT, PTEN expression levels in p62 transgenic mice were hypothesized to be 
altered, too. This was examined by Western Blot and real time PCR experiments.  
 
In p62 transgenic livers, a significant downregulation of the PTEN protein could be 
detected in liver extracts derived from 5 and from 10 week old transgenic mice. The 
tendency was the same for 2.5 week old mice, but could not be considered 
significant (Figures 38 A + B). 
 
A significant reduction in PTEN mRNA expression levels could be shown for 2.5 as 
well as for 10 week old p62 transgenic mice. The same tendency was measured for 5 
week old mice, but could not be considered significant (Figure 38 C). 
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Figure 38:  PTEN expression. 
A  PTEN protein in p62 mice at the age of 2.5, 5 and 10 weeks 
normalized to α-tubulin. 
B  Quantification of (A) expressed as the mean x-fold values ± S.E.M. 
Values of p<0.05 (*) and of p<0.01 (**) were considered statistically 
differentt from control animals of the respective age using student´ s t-
test. (2.5 weeks co: n=6, tr: n=7; 5 weeks co: n=4, tr: n=5; 10 weeks 
co: n=7, tr: n=6) 
C PTEN mRNA expression (%), representing the mean ± S.E.M. 
compared to control animals. Values of p<0.05 (*) and p<0.01 (**) 
were considered statistically significant in comparison to control 
animals of the respective age using student´ s t-test. (2.5 weeks co: 
n=8, tr: n=13; 5 weeks co: n=4, tr: n=6; 10 week co: n=8, tr: n=12) 
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3.13.2  PTEN in HepG2 cells 
 
p62 expression was knocked down by siRNA followed by determination of PTEN 
expression. In fact, 72 h after p62 siRNA-transfection of HepG2 cells, we measured a 
significant downregulation of PTEN, suggesting a causal effect of p62 on PTEN 
expression. This effect was not seen 48 h hours after p62 siRNA-transfection (Figure 
39). 
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Figure 39:  PTEN expression in HepG2 cells after p62 knockdown. 
mRNA expression of PTEN (%) in HepG2 cells 48 h and 72 h after 
p62 siRNA-mediated knockdown. Data represents the mean ± S.E.M. 
A value of p<0.05 (*) was considered statistically different from 
controls (= cells treated with InterferinTM transfection reagent only) 
using student´ s t-test. No statistically significant changes were 
detected for random siRNA-treated cells.  
 
3.14   Improved glucose tolerance 
 
Since histological analyses suggested metabolic changes in p62 transgenic animals 
at the age of 2.5 weeks, an intraperitoneal glucose tolerance test (IP-GTT) was 
performed at that age.  
 
Fasting levels of glucose were similar in control and p62 transgenic animals; also the 
end point values corresponded to the normoglycemic controls. The time course 
revealed a slight but not significantly improved glucose clearance of p62 transgenic 
animals at 30 min after glucose administration (Figure 40). 
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Since the observation was made that female mice display higher IGF2 levels and 
develop fatty livers to a higher extent than their male littermates, potential gender-
specific differences were assessed. 
 
Whereas the glucose tolerance distribution curve in male p62 transgenic mice did not 
reveal any significant differences in neither glucose uptake nor clearance (data not 
shown), in female p62 transgenic mice, however, a significant reduction of glucose 
levels at 30 min (69.5 ±10.8 %) and at 75 min (75.2 ± 15.1%) (both: p<0.05) in 
comparison to normoglycemic controls could be revealed.  
 
 
 
Figure 40: Glucose tolerance test. 
Blood glucose values of 2.5 week old p62 transgenic mice after i.p. 
injection of 10 µl/g body weight glucose (20%). Blood glucose values 
are expressed as mg/dl, representing the mean ± S.E.M. (control: 
n=17,  transgenic: n=11). 
 
 
The area under the concentration time curve (AUC) is useful for calculating the 
relative efficiency of the elimination of substances from the body (Current Protocols 
in Molecular Biology, unit 29 B.3.10 (Heikkinen 2007)).  
 
The AUC for both genders revealed trends towards a slight but not significant 
reduction in glucose metabolism (Figure 41). However, in p62 transgenic females the 
AUC was significantly lower compared to controls, meaning that blood glucose 
clearance is increased (Figure 41).  
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In summary, the results indicate enhanced glucose clearance, i. e. enhanced 
responsiveness to glucose in the presence of p62 in females. 
 
 
 
Figure 41: AUC of glucose levels.  
Values represent means ± S.E.M. integrated over 75 min. A value of 
p<0.05 (*) was considered statistically different from gender-specific 
controls using student´ s t-test. 
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4.  Discussion 
 
4.1   The p62 protein and HCC 
 
HCC is the primary malignant liver cancer and has a very poor prognosis of survival 
after diagnosis. In order to improve therapy and to prevent carcinogenesis, it is 
important to gain knowledge of the complex pathways involved in tumor 
development. These very complex mechanisms result from multiple aberrations in 
cell proliferation, apoptosis, cell metabolism, chronic inflammatory processes and 
genetic alterations (Ito, Urabe et al. 1995; Piao, Kim et al. 1997; Thorgeirsson and 
Grisham 2002; Koike 2007). Multiple epidemiological risk factors are known from the 
literature, which contribute to HCC development, among which hepatitis B and C 
virus infection as well as metabolic diseases like obesity and diabetes mellitus are 
the most important ones (Wong, Limm et al. 2000; Davies, Mason et al. 2004; Ruhl 
and Everhart 2004; Younossi, McCullough et al. 2004). 
 
4.1.1   p62 transgenic mice 
 
The p62 protein was originally isolated from patients suffering from HCC, where it 
was exclusively expressed in cancer nodules (Zhang, Chan et al. 1999). This 
exclusive expression of p62 in malignant tissue together with its appearance in fetal 
liver make it an oncofetal protein (Lu, Nakamura et al. 2001). Functional implications 
of the protein have as yet been completely unknown.  
 
Transgenic mice provide a powerful tool to study specific genes enabling to see what 
consequences result from gene silencing or overexpression. This is why p62 
transgenic mice were generated to examine the consequences of p62 
overexpression in the liver. This thesis comprises the first phenotypic 
characterization of these animals.  
 
Three different ages (2.5, 5 and 10 weeks of age) were analysed to examine a 
potential age-dependent expression rate of the p62 transgene. Indeed, with the p62 
mouse lineage, which was used to perform all experiments described in this work, an 
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impact of the strength of the p62 overexpression on the extent of the examined 
alterations could be confirmed.  
 
As seen in p62 transgenic animals, variegation of transgene expression, a 
heterocellular or mosaic expression pattern seen in all mice in a given transgenic 
line, is a frequently observed but unexplained phenomenon (Dobie, Mehtali et al. 
1997) so far. Although the integration site of the p62 transgene was not determined, 
it is known that the degree of heterocellular expression is determined at least in part 
of the site of integration. A respective position-effect variegation (PEV) was seen in 
mice with X-chromosome translocation (Henikoff 1992).  
 
Gene inactivation is associated with proximity to heterochromatic regions, which may 
spread along the chromosome and exert a repressive effect on the expression of 
flanking genes, and is also influenced by the cis-acting elements flanking the gene 
(Walters, Magis et al. 1996) and the presence of multiple copies of the transgene 
(Dorer and Henikoff 1997).  
 
Tetracycline controlled transcriptional regulation describes a reversible process of 
inducible activation (Tet-on) or silencing (Tet-off) of genes through administration of 
tetracycline and its derivatives, e. g. doxycycline (Hillen and Berens 1994) in the 
drinking water. In p62 transgenic mice, the tTA protein binds as a ‘tet’ operator to the 
HRP-CMVmin promotor, initializing mRNA expression of p62 exclusively in the liver, 
which is realized upon the liver enriched activator protein (LAP).  
 
To exclude that the induction of the p62 transgene occurred due to genetic 
predisposition, doxycycline was administered to p62 transgenic mice, which 
abrogated the expression of the transgene. As a consequence of the knockdown of 
p62 expression, IGF2 and H19 mRNA levels in fact decreased. These findings 
confirm the causal relation between p62 overexpression and IGF2 and H19 
induction. 
 
In general, correlation graphics showed that the increase in p62 expression resulted 
in higher IGF2 and/ or H19 levels. Moreover, correlation between the expression 
levels of IGF2 and H19 displayed that the increase of one gene is accompanied by 
 Discussion 105 
the increase of the other gene. Worth mentioning was that females expressed higher 
levels of the p62 transgene than their male littermates. Since also the metabolic 
growth factor IGF2 was expressed highest in females, a causal interaction can be 
suggested from this observation. 
 
Since immunostaining of p62 and IGF2 performed on serial sections of p62 
transgenic liver tissues confirmed the co-localization of both proteins in the cytoplasm 
of hepatocytes, a correlation on the protein level could be suggested. 
 
The experiments described in this work focus on the phenotypic characterization of 
liver-specific p62 overexpression in p62 transgenic mice. 
 
4.2   Phenotypic alterations 
 
4.2.1  Appearance of basophilic cell foci 
 
HE is a routine staining, giving a general overview of the cell morphology. Foci of 
cellular alterations can be classified as eosinophilic, basophilic, vacuolated, clear cell 
or mixed. Foci might progress to preneoplastic lesions and to carcinomas (Frith, 
Boothe et al. 1980; Ward and Lynch 1984).  
A first hint on a pathophysiological impact of p62 was given by the HE-stained 
sections as eosinophilic and basophilic foci appeared in the livers of p62 transgenic 
mice, whereas in controls eosinophilic cells predominated. Basophilic cell foci are 
considered to be one criterion required to diagnose cell malignancy, as this 
phenotype suggests a progressive cellular dedifferentiation (Su, Benner et al. 1997). 
The occurrence of basophilic cell foci in p62 transgenic mice might give a first hint on 
the implication of p62 in tumorigenesis. 
 
Concomitant with the HE staining results was the observation of Horie et al. in mice 
with a hepatocyte-specific PTEN null mutation (Horie, Suzuki et al. 2004): p62 
transgenic mice also demonstrated a central location of cell nuclei and a weakly 
eosinophilic staining of the cytoplasm of hepatocytes. 
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Liver architecture gave hints on an accumulation of neutral lipids as presumed from 
the occurrence of empty vacuoles in paraffin-embedded liver tissue of p62 transgenic 
mice. The evidence of a fatty liver phenotype was indicated by pale liver colour in 
other mouse models of NAFLD (Takahashi, Qi et al. 2004; Matsuzawa, Takamura et 
al. 2007), an observation also made in p62 transgenic animals. 
 
4.2.2  Fatty liver phenotype 
 
Changes in liver structure due to lipid accumulation have deleterious effects as they 
increase the risk of the development of diseases (Bugianesi, Leone et al. 2002). 
Metabolic disorders, such as obesity, lead to non-alcoholic fatty liver disease 
(NAFLD) resulting from enhanced accumulation of fat droplets in the liver (Polesel, 
Zucchetto et al. 2009). After a “second hit”, steatohepatitis is induced by 
inflammatory processes, then called NASH, which is followed by liver cirrhosis, 
possibly ending in HCC (Wasmuth 2007). Since a first hint on a pathophysiological 
impact of p62 was given by the HE-stained tissue sections, the presumed role of p62 
on the accumulation of fat droplets in hepatocytes was examined.  
 
Specific fat staining impressively revealed the phenotype of a fatty liver in a high 
proportion of 2.5 week old p62 transgenic animals, with females displaying more 
frequent accumulation of fat droplets than males. Accumulation of fat droplets within 
hepatocytes of p62 transgenic mice was finely dispersed; i. e. hepatocytes were not 
ballooned by the insertion of fat into the cytoplasm as found mostly in other genetic 
mouse models and in most cases of NAFLD (Burt, Mutton et al. 1998; Valls, 
Iannacconne et al. 2006). 
 
Two distinct patterns of fat droplets can be distinguished: macro- and microvesicular. 
The large droplet type (macrovesicular) is hallmarked by a single fat droplet, which 
displaces the nucleus (Burt, Mutton et al. 1998), whereas the small droplet type 
(microvesicular) shows a finely dispersed accumulation of fat droplets with no 
displacement of the nucleus. The microvesicular type is associated with hepatic 
dysfunction (Sherlock 1983), e. g. defects in ß-oxidation and might therefore 
represent a ‘first hit’ in subsequent malignant liver transformation. 
 
 Discussion 107 
Although during liver preparation single fatty livers were also noticed in older mice, 
this phenotype could only be proven as being significant in the youngest examined 
group of transgenic mice (2.5 weeks of age). This is on the one hand quite 
remarkable due to its early appearance during life. On the other hand, the fatty liver 
phenotype could be explained by the fact that 2.5 week old p62 transgenic animals 
express the highest IGF2 levels in comparison to their older siblings. Such an 
increase in IGF2 protein was also observed in fatty liver disease (FLD) in steatotic 
livers in humans (Chiappini, Barrier et al. 2006).  
 
The phenotype of a fatty liver clearly demonstrates the impact of p62 on changes in 
lipid metabolism. This can represent a ‘first hit’ in the initiation of a progressive liver 
disease, thereby contributing to HCC development. 
 
4.2.3  Disturbance in glycogen storage 
 
Glycogen is a polysaccharide consisting of several glucose molecules serving as a 
glucose reservoir within the body. Glycogen synthesis is located in the liver and 
changes in glycogen levels indicate metabolic disorders. From glycogen storage 
disease (GSD) it is known that a deficiency in the enzyme glucose-6-phosphatase 
impairs the ability of the liver to produce free glucose from glycogen and 
gluconeogenesis, resulting in hypoglycemia and hyperlipidemia, accompanied by an 
accumulation of glycogen and fat droplets in the liver (Burchell 1998). 
 
In rats with chemically induced liver cirrhosis a decrease in hepatic glycogen content 
was observed (Krähenbühl, Talos et al. 1996) and also in humans with alcohol-
induced liver cirrhosis reduced hepatic glycogen stores have been described (Owen, 
Reichle et al. 1981). Krähenbühl et al. could show that this is due to an impaired 
hepatocellular glycogen metabolism (Krähenbühl, Lang et al. 2003).  
 
The observed decrease of glycogen detected in 2.5 week old p62 transgenic livers 
might therefore represent an early stage of liver dysfunction. In this context, it is 
interesting to note that an inhomogenic distribution of glycogen was detected. 
Glycogen accumulation occured around the central veins, whereas Rappaport zone 2 
contained less glycogen. Similarily, rats display glycogen appearance in Rappaport 
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zone 1 after a fat-rich diet due to a disappearance of glycogen-synthesizing enzymes 
in Rappaport zone 2 (Chen and Katz 1988). This finding might suggest a link 
between glycogen and lipid changes evoked by p62 overexpression. 
 
The noticed decrease in glycogen storage is contradictory to the increased glycogen 
storage observed in mice with a liver-specific PTEN deletion (Stiles, Wang et al. 
2004). Interstingly, however, despite the fact that in p62 transgenic animals the 
PTEN gene was reduced at the age of 2.5 weeks, no change in AKT phosphorylation 
was detected. Since glycogen is synthesized in a pAKT-dependent fashion an 
increase of glycogen is not to be expected. 
 
A reexpression of IGF2 is associated with GSK-3 hyperphosphorylation in an in vivo 
mouse model of hepatocarcinogenesis (Desbois-Mouthon, Wendum et al. 2006), 
followed by inhibiton of glycogen synthase. Thus, preneoplastic liver lesions involve 
focal lack of glycogen storage (Bannasch, Klimek et al. 1997). Such a decrease in 
glycogen concomitant with an induction of IGF2 was also noticed in p62 transgenic 
animals, leading to the proposal that p62-mediated IGF2 overexpression results in 
changes in energy metabolism, which support the progression of malignant liver 
diseases.  
 
Moreover, the reduction of endogenous hepatic glycogen induced by p62 
overexpression could be a consequence of the accumulation of fat droplets within 
hepatocytes, which would disturb glycogen synthesis, as known from GSD 
(Bandsma, Smit et al. 2002). 
 
4.2.4  Metabolic alterations 
 
The interplay between glucose and lipid metabolism is triggered by the substrate 
uptake and distribution between peripheral tissues and the liver, as it was shown in 
several mouse models (Bruning, Michael et al. 1998; Abel, Smuts et al. 2001).  
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4.2.4.1 Increased liver to body weight ratio 
 
Association of the incidence and mortality of liver cancers with obesity was revealed 
in several studies, which showed a relationship between the high incidence of HCC 
in obese patients (Nair, Mason et al. 2002). Obesity is associated with decreased 
IGF2, which is a mitogen that stimulated cell growth (Gaunt, Cooper et al. 2001). 
 
The liver weight to body weight ratio displayed a significant increase in 2.5 week old 
p62 transgenic animals. This result corresponds to observations made in fatty livers 
developing in animals after feeding a high-fat diet (Otogawa, Kinoshita et al. 2007) or 
upon genetic manipulations (Wagener, Schmitt et al. 2006). Positive effects for IGF2 
on body and organ weights are reported (Zaina, Pettersson et al. 2003).  
 
4.2.4.2  Alteration of serum levels 
 
Regarding alterations in serum parameters, an increase in serum triglycerides (TG) 
in male p62 transgenic animals was detected, which was also found in mice with a 
liver-specific nuclear respiratory factor 1 (NRF-1) deletion, although gender-specific 
differences were not considered in this study (Xu, Chen et al. 2005). In contrast, 
female serum TG levels were lower as it was also shown in a work by Anezaki et al. 
working on PTEN k. o. mice (Anezaki, Ohshima et al. 2009). These results suggest 
that in p62 transgenic males, the redistribution of fat from other tissues to the liver 
and/ or an enhanced fat synthesis, or decreased lipolysis, might be changed upon 
p62 overexpression.  
 
The accumulation of TGs in p62 transgenic males could also be secondary to the 
reduction in glycogen storage. An increase in glycolysis leads to an enforced 
production of acetyl-CoA, which in turn stimulates lipogenesis, while at the same time 
inhibiting fatty acid oxidation in the liver. Fatty acids released after lipolysis are 
transported to the liver where they are used for triglyceride synthesis. This finally 
ends in steatosis due to the discrepancy between fatty acid uptake and synthesis on 
the one hand and fatty acid oxidation and release on the other hand (Bandsma, Smit 
et al. 2002). Furthermore, an impact on the rate of the synthesis of fatty acids and 
their secretion could probably be amplified through the p62-caused downregulation of 
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PTEN in p62 transgenic mice, as it was shown by Stiles after liver-specific PTEN 
deletion in mice (Stiles, Wang et al. 2004). 
 
4.2.5  Non-inflammatory phenotype 
 
The observations on changes in lipid and glucose metabolism arose the question 
whether p62 might not solely contribute to the ‘first hit’, i. e. fat accumulation, but also 
to the ‘second hit’, i. e. inflammation, thereby supporting the progression of a 
steatohepatits. In addition to the investigation of metabolic alterations in p62 
transgenic animals, experiments were performed to elucidate whether the fatty liver 
phenotype is accompanied by NASH, i. e. the simultaneous occurrence of 
inflammation besides fat acumulation. 
 
4.2.5.1  Absence of inflammatory parameters 
 
Acute inflammation is a necessary response to tissue injury, directed towards the 
restoration of normal tissue structure and/ or function. The dysregulation of 
inflammatory processes is involved in the pathogenesis of diseases. 
 
Elevated transaminase levels are parameters, which indicate inflammatory processes 
in the body. Both genders revealed a lack of transaminase increases, also observed 
in a genetic mouse model of NAFLD (Xu, Chen et al. 2005) suggesting a non-
inflammatory phenotype. Noteworthy in this context is the observation made by 
Hashimoto et al., which could reveal low levels of AST and ALT as independent 
predictors of HCC development in humans (Hashimoto, Yatsuji et al. 2009). To 
transcribe this result onto p62 transgenic mice would lead to the conclusion that the 
decrease in serum transaminase levels in the presence of the p62 transgene might 
contribute to the onset of HCC. 
 
On the other hand, Horie et al. demonstrated increased transaminase levels in 
hepatocyte-specific PTEN-deficient mice (Horie, Suzuki et al. 2004). This result is in 
contrast to the observation made in p62 transgenic mice. On the other hand, neither 
an increased in serum transaminase levels nor an accumulation of leukocytes could 
be revealed in 2.5 week old p62 transgenic livers.  
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4.2.5.2 Absence of NF-қB translocation 
 
NF-қB is a pivotal transcription factor involved in inflammatory processes. Upon 
activation, it translocates into the nucleus where it supports transcription of pro-
inflammatory proteins (Sen and Baltimore 1986). One step in the manifestation of a 
steatohepatitis is the support of inflammation besides fat accumulation. After 
translocation into the nucleus, NF-қB plays an important role in the initiation of a 
cascade leading to liver injury. It mediates the inductions of adhesion molecules and 
chemokines and thereby the recruitment of neutrophilic cells into the liver. 
Sequestered neutrophils release proteases and reactive oxygen species, which 
directly damage hepatocytes and endothelial cells causing hepatic hypoperfusion 
(Jaeschke 1996; Vollmar, Schmidt et al. 1996). 
 
Several studies revealed the significance of the NF-қB p65 subunit in hepatocytes, 
which directly acts to promote cell survival (Verma, Stevenson et al. 1995; Bellas, 
FitzGerald et al. 1997). Schoemaker et al. showed that NF-қB regulates members of 
the inhibitor of apoptosis protein family (IAP) in hepatocytes, leading to an inhibition 
of caspase activity, thereby preventing apoptosis (Schoemaker, Ros et al. 2002). 
Moreover, studies revealed the implication of NF-қB activation in the progression of 
NASH (Luedde, Beraza et al. 2006; Luedde, Beraza et al. 2007). 
 
Interstingly, a high proportion of p62 transgenic hepatocytes showed a distinct 
increase in cytoplasmic NF-қB p65.  
 
Constitutive overexpression of the p65 protein has previosly been shown in thyroid 
carcinoma cells (Visconti, Cerutti et al. 1997) and an increased cytoplasmic staining 
of the NF-кB subunit p65 has also been demonstrated in malignant epithelial cells 
from colorectal tissue compared to normal epithelium (Charalambous, Lightfoot et al. 
2009). Moreover, it has been demonstrated that the oncogene MDM2 induces protein 
expression of the NF-қB p65 subunit in acute lypmphoblastic leukemia (Gu, Findley 
et al. 2002). From carcinoma cells it has been reported that NF-қB and IкK are linked 
in an autoregulatory loop, i. e. the p65 subunit itself stimulates IкK expression, which 
in turn results in self-inactivation (Scott, Fujita et al. 1993; Sun, Ganchi et al. 1994). 
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This observation could explain an enhanced cytoplasmic staining in the absence of a 
translocation into the nucleus in p62 transgenic hepatocytes. 
 
Although functional implications of increased levels of the regulatory NF-қB p65 
subunit in cancerogenesis are as yet largely unknown, they might enhance an 
inflammatory response upon respective stimuli. Whereas fat accumulation as 
coalesced lipid droplets in hepatocytes of p62 transgenic animals forms the 
borderline from a benign to a morbid condition (Neuschwander-Tetri 2005), the 
results from the investigations within this thesis confirme a non-inflammatory 
phenotype, i. e. the ‘second hit’ towards the progression of NASH, resulting from 
inflammation, is missing. 
 
4.3  Increased IGF2 and H19 expression 
 
The interaction of p62 with tumor-related factors was suggested due to the 
upregulation of IGF2 and H19 expression (Leighton, Saam et al. 1995) The use of 
doxycycline excluded that the overexpression of the three genes occurred due to 
genetic predisposition. Within one age group the extent of p62 correlated with the 
expression of IGF2 and H19.  
 
In order to address the question which steps in gene expression of IGF2 and H19 are 
modulated by p62, a set of experiments was performed, elucidating the possible 
impact on mRNA stability and on chromosomal changes. 
 
4.3.1  Absence of transcriptional stability changes 
 
Regulation of gene expression is used to turn the information of genes into gene 
products, either protein or RNA. The regulatory steps are versatile, reaching from 
chromatin domains, transcription, post-transcriptional modification, RNA transport, 
translation, mRNA degradation up to post-translational modification. Any step in gene 
expression can be modulated (Alberts 1992). The regulation of mRNA decay is a 
major control point in gene expression. Regulated mRNA stability is achieved either 
through cis-acting elements within mRNA (poly (A) tail, 3´- and 5´-untranslated 
regions, mRNA coding region) or by trans-acting regulatory factors (Ross 1995). One 
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way that dictates mRNA stability is mediated by mRNA binding proteins. Since p62 
was shown to belong to the family of IGF2 mRNA-binding proteins (IMPs) (Lu, 
Nakamura et al. 2001) and IMPs have been regarded to bind to H19 (Runge, Nielsen 
et al. 2000), IMPs are potential candidates to influence mRNA stability. 
 
Since the causal relationship of the upregulation of IGF2 and H19 in p62 transgenic 
mice still remained ambiguous, experiments to elucidate a regulation on the 
transcript level were performed on isolated hepatocytes. However, the results 
revealed no influence of p62 on mRNA stability of IGF2 and H19.  
 
Since both mRNAs turned out to be a rather stable mRNA (t1/2>10 h) the regulation 
via stabilizing mechanisms would be rather unexpected since stability-regulatory 
genes mostly regulate short-lived mRNAs (Eberhardt, Doller et al. 2007) 
 
Further transcriptional mechanisms of p62-evoked IGF2 upregulation are 
conceivable, as IGF2 is subjected to differential polyadenylation, alternative splicing, 
site-specific endonucleolytic cleavage, and postsecretory attenuation of IGF2 
function by IMPs (Sussenbach, Steenbergh et al. 1992; Stewart and Rotwein 1996).  
 
The similar spatiotemporal expressions of the IGF2 and H19 mRNAs as well as their 
complex counter-regulatory actions (Brannan, Dees et al. 1990) are characteristics 
that show the functional coupling of both genes. The putative role of the IMP-family 
member p62 in the upregulation of IGF2 and H19 mRNA levels could therefore result 
from IGF2-mediated induction of H19 mRNA, implicating a trans effect of H19 caused 
by p62 overexpression, as it was shown by Li et al. (Li, Franklin et al. 1998). 
 
Moreover, the maintainance of elevated IGF2 mRNA levels could be explained by the 
fact that H19 mRNA can bind four molecules of IMP1, which in turn binds to the 5´ 
UTR of IGF2 mRNA, thereby promoting post-transcriptional or translational IGF2 
expression (Runge, Nielsen et al. 2000).  
 
Mice with a targeted deletion of IMP1 display growth retardation accompanied by 
IGF2 downregulation (Hansen, Hammer et al. 2004). This suggests a general IGF2-
elevating action of IMPs. In fact, the expression patterns of IMPs and IGF2 overlap in 
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many tissues suggesting a controlling function on the production of IGF2 mRNA 
(Hansen, Hammer et al. 2004) 
 
4.3.2  Monoallelic expression of IGF2 and H19 
 
Both transcriptional as well as chromosomal changes could account for the 
upregulation. As no effects on mRNA turnover of IGF2 and H19 were detected in p62 
transgenic animals, implications on possible genetic alterations of the chromosomal 
expression of IGF2 and H19 evoked by p62 were examined.  
 
The oppositely imprinted genes IGF2 and H19 often show coordinate, reciprocal 
regulation (Ohlsson, Hedborg et al. 1994; Liu, Kahri et al. 1995). Imprinted 
expression is reciprocally controlled by a common CpG island located upstream of 
H19, which shows parent-specific methylation. Methylation alterations at this site are 
correlated with abnormal IGF2 and H19 expression and are linked to many tumors 
(Cui, Niemitz et al. 2001; Takai, Gonzales et al. 2001). 
 
Li et al. found parallel expression of IGF2 and H19 in HCC (Li, Nong et al. 1997). The 
overexpression of IGF2 was not only demonstrated in about 20% of human HCC 
(Cariani, Lasserre et al. 1988) but has also been detected in HCCs in transgenic 
mice (Schirmacher, Held et al. 1992).  
 
IGF2 is a growth factor, which is known to promote tumorigenesis after switching 
from mono- to biallelic expression (Kim and Lee 1997). But also loss of imprinting 
(LOI) of IGF2 was described in tumors (Kondo, Suzuki et al. 1995; Kim, Choi et al. 
1998). LOI of IGF2 in HCC is uncoupled from the downregulation of H19 expression 
but rather associated with coexpression for H19 and IGF2 (Ariel, Ayesh et al. 1997). 
Another common feature of human HCC which explains the frequent loss of biallelic 
IGF2 expression is explained by the disruption of the IGF2 promotor region, 
particularly the loss of the P1 activity (Li, Nong et al. 1997). 
 
The role of the untranslated RNA H19 in tumorigenesis is described controversely. 
By now, several studies indicate a tumor suppressor activity but also the necessity of 
H19 in tumor growth has been shown (Matouk, DeGroot et al. 2007; Yoshimizu, 
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Miroglio et al. 2008). Its implication for HCC development has been underlined in a 
mouse model of HCC, where diethylnitrosamine, a known carcinogen of the liver, 
induced H19 mRNA expression (Graveel, Jatkoe et al. 2001). Moreover, H19 
transcription was initiated after binding of c-myc near the imprinting control region 
(ICR) (Barsyte-Lovejoy, Lau et al. 2006). Consistent with the theory of H19 being a 
tumor suppressor gene (Yoshimizu, Miroglio et al. 2008) is the fact that 
tumorigenicity was ablated in vivo in nude mice after transfection with an H19 
expression construct (Hao, Crenshaw et al. 1993).  
 
For both examined ages, neither a change in allele-specific nor biallelic expression 
was detected for IGF2 and H19. This result is in concordance with the observation 
made by Feinberg et al. (Feinberg and Vogelstein 1983), leading to the conclusion 
that p62 does not contribute to the upregulation of the both genes through genetic 
alterations.  
 
One possible mechanism of p62 might be to change the DNA methylation pattern, 
since it is known from the literature that parent-specific methylation patterns have 
been detected in endogenous imprinted genes (Sasaki, Jones et al. 1992; Ferguson-
Smith, Sasaki et al. 1993; Reik and Allen 1994). The methylation of the paternal 
allele of IGF2 in the 3´ region correlates directly with expression and might therefore 
be a target for p62 (Feil, Walter et al. 1994). p62 could contribute to high IGF2 
expression levels by maintaining the methylation level high.  
 
The observed result from this experiment that LOI of the IGF2 locus is not involved in 
increased IGF2 gene expression in p62 transgenic animals has also deen described 
in HCC (Kaneda and Feinberg 2005).  
 
An accelerated liver tumor development was demonstrated in the absence of H19 
(Yoshimizu, Miroglio et al. 2008). Upregulated H19 expression could therefore 
account for the prevention of liver tumor development in p62 transgenic mice by 
antagonizing the tumorigenic potential of IGF2 and IGF2-induced metabolic 
alterations. In fact, H19 expression might also contribute to IGF2 downregulation at 
higher age (Leighton, Saam et al. 1995). 
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4.3.3  Silencing of p62 
 
siRNA-mediated knockdown is a RNA-dependent gene-silencing process that is 
controlled by the RISC complex, initiated by short double-stranded RNA molecules 
(Hannon 2002).  
 
Gene silencing by siRNA-mediated gene knockdown of p62 in human hepatoma 
cells, followed by the examination of IGF2 and H19 mRNA expression, was 
performed in order to address the relationship between the simultaneously occurring 
overexpression of the three genes in a human system. Indeed, a detected reduction 
in p62, IGF2 and H19 mRNA expression levels demonstrated the direct correlation.  
 
This experiment proved significance of the in vivo findings in mice also on the human 
level.  
 
A conceivable therapeutic treatment with siRNA could be gene-silencing of p62 to 
attenuate metabolic effects resulting from IGF2 expression. 
 
4.4  IGF2 downstream effects 
 
Although the detailed mechanisms how p62 increases IGF2 expression remain to be 
clarified, its downstream actions lead to severe pathophysiological consequences. 
They are most likely exerted by IGF2. Increased IGF2 expression in the absence of 
macroscopic signs of inflammation has been demonstrated in human steatosis 
(Chiappini, Barrier et al. 2006). These findings suggest IGF2 as a pathophysiological 
factor in fatty liver disease. Therefore, a second set of experiments performed within 
this work concentrated on downstream effects exerted by IGF2.  
 
4.4.1  Decreased PTEN expression 
 
Since IGF2 is known to mediate cell survival signals through the PI3-kinase pathway, 
experiments focused on the expression of two proteins within this cascade, i. e. 
PTEN and pAKT (Kandel and Hay 1999). Upon activation of PI3-kinase after initial 
binding of IGF2 to its receptor, PIP3 is generated. This molecule leads to the 
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activation of AKT through phosphorylation (Franke, Hornik et al. 2003). In contrast, 
PTEN is able to dephosphorylate PIP3 and thereby participates in the reciprocal 
regulation of AKT activity (Franke, Hornik et al. 2003).  
 
Experiments revealed attenuated PTEN expression in the presence of the p62 
transgene. This result could give a first hint on a potential participation of p62 in the 
development of HCC, as PTEN is a tumor suppressor gene and deletion of the PTEN 
gene as well as reduced PTEN expression was shown to be implicated in diverse 
tumors (Di Cristofano and Pandolfi 2000).  
 
Unsaturated fatty acids are known to downregulate PTEN expression (Terrettaz and 
Jeanrenaud 1983). It might therefore be possible that the reduction of PTEN 
expression in p62 transgenic animals at the age of 2.5 weeks results from the 
increase of free fatty acids, which accumulated in hepatocytes, as it was shown in 
liver-specific PTEN deficient mice, which displayed NASH (Stiles, Wang et al. 2004). 
On the other hand, the lipid phosphatase activity of PTEN controls the intracellular 
triglyceride content as shown in HepG2 when PTEN depletion resulted in enhanced 
accumulation of triglycerides (Vinciguerra and Foti 2008). Vice versa, unsaturated 
fatty acids are thought to contribute to the development of liver injury through their 
induction of a PTEN downregulation (Vinciguerra, Sgroi et al. 2009). An impact on 
the rate of the synthesis of fatty acids and their secretion by p62-induced IGF2 might 
be amplified through the p62-caused downregulation of PTEN as shown in the past 
through a liver-specific PTEN deletion in mice (Stiles, Wang et al. 2004). 
 
Since fatty acids play a role in PTEN downregulation (Vinciguerra, Carrozzino et al. 
2009), one might suggest that a reduction in PTEN expression is secondary to fatty 
liver induction. This is further supported by the observation of liver regeneration from 
pathophysiological to physiological conditions with increased age concomitant with a 
decline in IGF2 mRNA expression. The shared regulation of IGF2 and PTEN has 
also been shwon in several cancer cells (Perks, Vernon et al. 2007). 
 
Moreover, results are supported by the observations made in the study of Moorehead 
et al. where a negative feedback loop of IGF2 on PTEN was observed, i. e. IGF2 
induction itself inhibits PTEN expression (Moorehead, Hojilla et al. 2003).  
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To underline the relationship of p62 overexpression and PTEN downregulation found 
in p62 transgenic mice, PTEN transcript levels were determined in human hepatoma 
cell lines after siRNA-mediated knockdown of p62. The increase in PTEN mRNA 
levels correlated with the decrease in mRNA levels determined for p62, thereby 
underlining the theory that p62 promotes tumorigenesis by inhibiting PTEN activity. 
The contradictory result 72 h after p62 knockdown, i. e. the detection of elevated 
PTEN transcript levels, could be explained by a partical degradation of siRNA 
molecules, thereby allowing the recovery of p62 mRNA levels.  
 
4.4.2  Increased phosphorylation of AKT/protein kinase B 
 
Growth promoting as well as metabolic effects of IGF2 are mediated upon binding to 
the IGF-1R. This follows the activation of downstream signal transduction pathways, 
mainly the activation of PI3-kinase. The signaling cascade following AKT activation is 
rather complex, not only apoptosis is inhibited but also metabolic and proliferative 
effects are exhibited (Cardone, Roy et al. 1998; Crowder and Freeman 1998; Diehl, 
Cheng et al. 1998; Gille and Downward 1999). Increased IGF2 expression thereby 
leads to constitutive AKT activation (Andjelkovic, Alessi et al. 1997; O'Connor 1998; 
O'Dell and Day 1998). 
 
The significant increase in AKT phosphorylation in p62 transgenic animals might 
therefore be explained by p62-mediated IGF2 induction. On the other hand, it has to 
be kept in mind that AKT phosphorylation culminated with increased age, while at the 
same time impaired IGF2 expression was detected.  
 
PTEN and pAKT are reciprocally regulated through the ability of PTEN to 
dephosphorylate the AKT activator PIP-3 (Parsons and Simpson 2003). Therefore, 
PTEN downregulation could support the IGF2-caused induction of AKT 
phosphorylation observed in p62 transgenic animals, thereby contributing to a 
progressive AKT activation. 
 
AKT has also been suggested to promote tumorigenesis as it appears to be 
hyperactivated in the majority of human cancers (Hay 2005; Hennessy, Smith et al. 
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2005). p62 overexpression might therefore contribute to tumor development as it 
leads to a constitutive activation of AKT. 
 
Upon AKT phosphorylation, GSK-3 is inhibited, ending in an enhanced glycogen 
synthesis in the liver (Cross, Alessi et al. 1995). Nevertheless, 2.5 week old p62 
transgenic animals displayed reduced glycogen levels. Since no increase in AKT 
activation was detected for that age group, this result might support the conclusion 
that an effect of AKT on GSK-3 could be neglected at the age of 2.5 weeks.   
 
4.4.3   Apoptosis protection  
 
Hepatocyte apoptosis is a cardinal feature of NAFLD and NASH and emerges as a 
critical mechanism contributing to the progression of liver diseases (Feldstein, 
Canbay et al. 2003; Wieckowska, Zein et al. 2006). On the other hand, apoptosis 
protection has been associated with poor prognosis of HCC (Ito, Monden et al. 
2000). 
 
In contrast to necrosis, which results from acute cellular injury, apoptosis describes a 
process of programmed cell death. Upon release of cytochrome c, a protein complex, 
the apoptosome, is formed which in turn activates the caspase cascade, triggering a 
cascade of caspase activation events leading to apoptosis (Li, Bergeron et al. 1997; 
Li, Nijhawan et al. 1997). 
 
Caspase-3 activation plays a key role in the initiation of cellular events during the 
early apoptotic process. After induction of apoptosis through Act D and TNF-α, 
detection of caspase-3 activity was measured in cellular lysates from isolated 
hepatocytes.  
 
The fatty liver phenotype and the constitutive AKT activation gave hints that 
apoptosis might be altered under p62 overexpression. 
 
In fact, after induction of apoptosis through Act D and TNF-α, caspase-3 activity was 
significantly lower in hepatocytes from p62 transgenic animals and can be explained 
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by the implication of AKT in caspases inhibition upon activation through 
phosphorylation (Cardone, Roy et al. 1998).  
 
Apoptosis inhibition results in a survival advantage of malignant cells, which in 
second line can convert to tumor cells, promoting carcinogenesis. Several studies 
demonstrated that the induction of apoptosis resulted in tumor regression (Hood and 
Cheresh 2002; Motoki, Mori et al. 2005). The results clearly support the theory of p62 
as a promotor of tumor progression. 
 
4.5  Improved glucose tolerance 
 
Insulin is the primary hormone involved in glucose homeostasis and in the stimulation 
of glucose transport. Insulin resistance is a common pathophysiological state in 
which target tissues fail to respond properly to normal levels of circulating insulin. 
Thereafter, impaired glucose tolerance can develop. Since the levels of circulating 
free fatty acids are thought to play a significant role in the establishment of insulin 
resistance (Shulman 2000), IP-GTT was performed.  
 
p62 transgenic mice demonstrated a non-significant decrease in the area under the 
curve (AUC). However, this decrease was demonstrated to be significant in p62 
transgenic females. 
 
The gender differences might simply reflect the observation that females expressed 
higher levels of the p62 transgene than their male littermates. Since also the 
metabolic growth factor IGF2 showed increased expression in females, a causal 
interaction can be suggested.  
 
The observation is in concordance with the improved glucose tolerance measured 
after liver-specific PTEN deletion in mice (Stiles, Wang et al. 2004). In this study, 
after an i. p. glucose load, the peak glucose concentration was lower and displayed a 
faster decline towards the basal level indicating an enhanced glucose disposal.  
 
The results might display an increased ability of p62 transgenic animals to clear 
glucose.
 Summary 121 
5. Summary 
 
This study represents the first phenotypic characterization of mice showing a liver-
specific expression of the IGF2 mRNA-binding protein p62. It clearly demonstrates 
the interaction between p62/IGF2 and H19 expression in p62 transgenic mice and in 
human hepatoma cell lines and elucidates several effects of p62 on apoptosis 
regulation and metabolism. 
 
Since p62 belongs to the IGF2 mRNA binding proteins, investigations were made on 
the expression level of IGF2 mRNA. An increase in IGF2 as well as the reciprocally 
imprinted H19 mRNA could be verified. This effect did neither originate from changes 
in allele-specific gene expression nor from alterations in mRNA turnover.  
 
To elucidate the downstream effects of IGF2 induction caused by p62 
overexpression, the focus concentrated on the PI3-kinase pathway, known to 
regulate metabolism and apoptosis. Several experiments within this work 
demonstrated a reduction in PTEN gene expression concomitant with an increase in 
AKT phosphorylation, resulting in the prevention of p62 transgenic hepatocytes from 
undergoing apoptosis.  
 
In this study, the most prominent alteration discovered was a fatty liver phenotype in 
p62 transgenic mice accompanied by a decrease in glycogen storage. This indicated 
a rise in the usage of glucose for lipogenesis. The fatty liver phenotype displayed 
improved glucose tolerance, at least in female mice.  
 
Taken together, our data provide evidence that the oncofetal tumor-associated 
autoantigen p62 plays a distinct pathophysiological role in liver disease. Its 
overexpression induced both a fatty liver and an anti-apoptotic phenotype. These 
findings suggest that the observed increase of p62 expression during transition from 
liver disease to cancer has a causal role in disease progression. Alterations of p62 
levels might therefore serve as both a diagnostic marker and as a pharmacological 
target.
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6.  Outlook 
 
Further studies are necessary to elucidate the distinct pathophysiological role of the 
oncofetal tumor-associated autoantigen p62 in order to use p62 both as a diagnostic 
marker and as a pharmacological target.  
 
Since the pathways involved in the progression of the fatty liver phenotype are 
largely unknown and due to findings that the ratio of saturated to unsaturated fatty 
acids contributes to metabolic changes, gas chromatography experiments could give 
hints into the lipid composition of p62 transgenic livers.  
 
By now, the molecular pathways involved in the accumulation of fat droplets under 
p62 overexpression remains to be elucidated.  
Since the lipogenesis-promoting gene sterol regulatory element-binding protein 1 
(SREBP1) is known to play a significant role in hepatic steatosis through the 
regulation of the synthesis and storage of fatty acids in the liver, investigations on 
SREBP1 expression levels might be of interest.  
Another potential candidate might be the transcription factor peroxisome proliferator-
activated receptor gamma (PPAR-γ), as PPAR-γ deficient mice display massive 
steatosis.  
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7.  Supplement 
7.1   PCR primer 
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7.2  Taq Man probes 
 
probe name sequence 5´- 3´ 
hu-p62-FAM-BHQ 6-FAM d(TGT GAA TCT CTT CAT CCC AAC CCA GGC T) BHQ-1 
IGF2-FAM-BHQ 6-FAM d(CCT TCG CCT TGT GCT GCA TCG CTG CT) BHQ-1 
H19-FAM-BHQ 6-FAM d(TCA CTG AAG GCG AGG ATG ACA GGT GTG G) BHQ-1 
18S-FAM-BHQ 6-FAM d(CCA CGC CAA CCC ACC GCC CTG TG) BHQ-1 
Cyclophilin-FAM-BHQ 6-FAM d(TGG GCC GCG TCT CCT TCG A) BHQ-1 
 
7.3   Real-time PCR conditions using Taq Man probes 
 
gene 
amount of Taq Man 
probe  
Mg2+ concentration  
annealing 
temperature 
number of cycles 
hu p62 1.5 pmol 5 mM 60°C 40 
mu IGF2 1.5 pmol 4 mM 60°C 40 
mu H19 2.5 pmol 3 mM 60°C 40 
mu 18S 2.5 pmol 3 mM 60°C 45 
cyclophilin 1.5 pmol 3 mM 60°C 45 
mu p62 2.5 pmol 5 mM 60°C 40 
  
7.4   Real-time PCR conditions using SYBR green 
 
gene Initial 
denaturation 
(94°C) 
Denaturation 
(94°C) 
annealing 
(60°C)  
Elongation 
(72°C) 
number of cycles 
β- actin 10 min 10 sec 15 sec 15 sec 40 
hu p62 10 min 10 sec 15 sec  15 sec 40 
hu H19   5 min 30 sec 30 sec 30 sec 40 
hu IGF2   5 min 30 sec 30 sec 30 sec 40 
PTEN 10 min 15 sec 15 sec 15 sec 45 
mu 18S   8 min 15 sec 15 sec 15 sec 40 
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7.5 Antibodies 
 
antibody isotype Dilution  
monoclonal anti-α-tubulin mouse IgG1 1/500 in RBB 
phospho-AKT (Ser 473) rabbit IgG1 1/1000 in RBB 
PTEN rabbit IgG1 1/1000 in RBB 
hu p62 (Western Blot) human IgG1 1/1000 in RBB 
goat anti-rabbit Irdye® 680 rabbit IgG, whole molecule 1/5000 in RBB 
goat anti-mouse Irdye® 800 CW mouse IgG, whole molecule 1/5000 in RBB 
hu p62 (immunohistology) rabbit IgG1 1/500 in DRA 
IGF2 (immunohistology) rabbit IgG1 1/100 in DRA 
NFқB (immunohistology) rabbit IgG1 1/100 in DRA 
 
RBB= Rockland blocking buffer (purchased from Biomol, Hamburg, Germany) 
DRA= DakoREALTM Antibody diluent (purchased from DAKO, Hamburg, Germany) 
 
7.6 siRNA  
 
code name sequence purchased from 
hu p62 siRNA Hs-IMP-2_2_HP siRNA r(GGG UAG AUA UCC AUA GAA A)dTdT Qiagen, Hilden, 
Germany 
random 
siRNA 
siGENOME non-targeting 
siRNA #2 
including non-targeting siRNAs #2-#5, 
targeting firefly luciferase 
Dharmacon, Thermo 
Fisher Scientific,  
Bonn, Germany 
 
7.7 Molecular weight markers 
 
PageRulerTM Prestained Protein Ladder (Fermentas, St.Leon- Rot, Germany) 
1 kb DNA ladder (Invitrogen, Karlsruhe, Germany) 
50 base-pair ladder (Amersham, GE Healthcare, Munich, Germany) 
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7.8  Solutions and buffers 
 
7.8.1  Cell culture media 
 
Cell culture medium (hepatoma cell lines) 
RPMI containing 
10% FCS gold 
1% penicillin/streptomycin 
2 mM L-glutamine stock 
 
L-glutamine stock 
200 mM L-glutamine  
 
Cell culture medium (primary murine hepatocytes) 
Gibco Williams E with GlutaMax 
10% FCS 
1% penicillin/streptomycin 
0.1% gentamycin 
 
7.8.2  Solutions for primary murine hepatocyte isolation 
 
EGTA stock, pH 7.6 
125 mM EGTA 
 
Calcium chloride stock (CaCl2) 
130 mM CaCl2*2 H2O 
 
Magnesium sulfate stock (MgSO4) 
100 mM MgSO4*7 H2O 
 
KH-stock, pH 7.4 
1 M NaCl 
23 mM KCl 
12 mM KH2PO4 
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HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.6 or pH 8.5 
252 mM HEPES 
 
Glucose stock 
50 mM Glucose 
 
L-glutamine stock 
200 mM L-glutamine 
 
Amino-acid solution mix, pH 7.6 (sterile filtrated, stored at -20°C) 
0.27 g/l L alanine 
0.14 g/l L-aspartate-acid 
0.40 g/l asparagine 
0.27 g/l citrulline 
0.14 g/l L-cysteine 
1.0 g/l L-histidine 
1.0 g/l L-glutamine-acid 
1.0 g/l L-glycine 
0.4 g/l L-isoleucine 
0.80 g/l L-leucine 
1.30 g/l L-lysine 
0.55 g/l L-methionine 
0.65 g/l L-ornithine 
0.55 g/l L-phenylalanine 
0.55 g/l L-proline 
0.65 g/l L-serine 
1.35 g/l L-tryptophane 
0.55 g /l L-tryrosine 
0.80 g/l L-valine 
 
EGTA perfusion solution 
25 mM Glucose stock 
20 mM HEPES, pH 8.5 stock 
0.4 mM L-glutamine stock 
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0.4 mM EGTA stock 
12% amino acid solution mix 
8% KH stock 
 
Collagenase perfusion buffer 
30 mM glucose stock 
9.6% KH stock 
24 mM HEPES, pH 8.5 stock 
15% amino acid solution mix  
5 mM CaCl2 stock 
2 mM L-glutamine stock 
~0.25 g/l collagenase H 
 
Suspension buffer 
31 mM glucose stock 
25 mM HEPES, pH 7.6 
15% amino acid solution mix 
10% KH stock 
1 mM CaCl2 stock 
0.4 mM MgSO4 stock 
2 mM L-glutamine  
2 g/l BSA (bovine serum albumine) 
 
7.8.3  Solutions for Western Blotting 
 
Moini lysis buffer (proteins) 
50   mM Tris-HCl, pH 7.2 
150 mM NaCl 
1.0% Triton X-100 
0.5% sodium deoxycholat 
0.1% SDS (sodium dodecyl sulphate) 
1 mM EGTA 
25 mM NaF 
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(add immediately before use): 
1 mM sodium orthovanadate 
1 mM PMSF 
14% complete mini (7x) 
 
Running buffer (Western Blotting) 
25 mM Tris base 
86 mM glycin 
1% SDS (10% stock) 
 
Transfer buffer (Western Blotting) 
25 mM Tris base 
86 mM glycin 
0.5% SDS (10% stock) 
20% methanol 
 
Collecting gel stock, pH 6.8 
0.5 M Tris base 
0.4% SDS 
 
Separating gel stock, pH 8.8 
1.5 M Tris base 
0.4% SDS 
 
10 % SDS PAGE separating gel composition 
25% separating gel stock 
33% Rotiphorese gel 30 (Roth) 
1% APS (10%) 
1% SDS (10%) 
0.1% TEMED  
39.5% H2O 
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5% collecting gel for SDS- PAGE  
12% collecting gel stock 
16% Rotiphorese gel 30 (Roth) 
1% APS (10%) 
1% SDS (10%) 
0.1% TEMED 
68% H2O 
 
PBS, pH 7.4 
150 mM NaCl 
3 mM KCl 
10 mM Na2HPO4*2 H2O 
1.4 mM KH2PO4 
 
PBST, pH 7.4 
PBS, pH 7.4 
0.05% Tween 20 
 
7.8.4  Solutions for caspase measurements 
 
Lysis buffer (caspase activity) 
5 mM MgCl2 
1 mM EGTA 
0.1% Triton X-100 
25 mM HEPES, pH 7.5  
1 mM Pefabloc SC 
1 µg/ml Aprotinin/ Leupeptin/Pepstatin A 
 
Substrate buffer (caspase activity), pH 7.5, (store at 4°C) 
50 mM HEPES, pH 7.5 
1% sucrose 
0.1% CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate) 
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DTT stock (store at -20°C) 
1 M DTT (Dithiothreitol) 
 
Ac-DEVD-AFC (stock), (store at -20°C) 
10 mM ac-DEVD-AFC 
 
7.8.5  Material for SNuPE analysis 
 
SNuPE extension mastermix 
50 mM Tris-HCl, pH 9.5 
2.5 mM MgCl2  
0.05 mM ddTTP 
0.05 mM ddCTP 
3.6 µM SNuPE primer 
0.25 U Termipol [Solis BioDyne] 
 
SNuPE buffer A 
0.1 M triethylammonium acetate (TEAA) 
 
SNuPE buffer B 
0.1 M triethylammonium acetate (TEAA) and 25% acetonitrile 
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